Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
07/2009 | Recent  |  14: Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions July category listing 07/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
07/30/2009 > patent applications in patent subcategories. category listing

20090192072 - Insulin and igf-1 receptor agonists and antagonists: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090192071 - Use of photodynamic therapy to enhance treatment with immuno-modulating agents: Methods of enhancing the efficacy and safety of treatment with immuno-modulating agents are provided. The inventive methods combine treatment with immuno-modulating agents with photodynamic therapy (PDT). PDT can be administered before, during or after administration of the immuno-modulating agent. Combination therapy achieves at least the same efficacy as immuno-modulatory therapy... Agent: Foley And Lardner LLP Suite 500

20090192073 - Method for producing insulin analogs having a dibasic b chain terminus: The invention relates to a method for producing a type of insulin by genetically engineering a precursor thereof and converting said precursor to the respective insulin in an enzyme-catalyzed ligation reaction with lysine amide or arginine amide, or by lysine or arginine which is modified by protective groups, and optionally... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090192075 - Amylin formulations: A combined insulin and amylin and/or GLP-1 mimetic formulation has been developed wherein the pH of the insulin is decreased so that the amylin and/or GLP-1 remains soluble when mixed together with the insulin. In the preferred embodiment, a bolus insulin is administered by injection before breakfast, providing adequate bolus... Agent: Pabst Patent Group LLP

20090192074 - Methods and pharmaceutical compositions for healing wounds: A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected... Agent: Fulbright & Jaworski, LLP

20090192076 - Recombinant vwf formulations: The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.... Agent: Baxter Healthcare Corporation

20090192078 - Methods for diagnosis of cardiovascular disease: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.... Agent: Wolf Greenfield & Sacks, P.C.

20090192077 - North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus: A method for the prevention or treatment of Kaposi's sarcoma or Kaposi's sarcoma-associated herpes virus infection by administering an effective amount of a cyclopropanated carbocyclic 2′-deoxynucleoside to an individual in need thereof is provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090192079 - Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen: The present invention relates to a heparin-derivatized collagen matrix comprising a fragment of heparin covalently linked to a collagen scaffold, wherein the fragment of heparin has molecular weight of less than about 15 kDa, and at least one heparin-binding growth factor (HBGF) or heparin-binding adeno-associated virus (HB-AAV) or a combination... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090192081 - Casein derived peptides and uses thereof: Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the αS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090192080 - Cerberus/coco derivatives and uses thereof: The invention relates to Cerberus/Dan/Gremlin polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11. Preferred polypeptides are Coco or Cerberus derivatives.... Agent: Ropes & Gray LLP

20090192084 - Compositions and method of treating hypoxia-associated diseases: Hypoxia, a state of lower than normal tissue oxygen tension, has recently been implicated in a host of human diseases, including cancer, heart disease, and neurological disorders. Novel associations between p97 and other proteins, including UBX-domain-containing proteins (UBX-polypeptides), HIF1α, and a variety of E3 ligases are provided herein. The disclosure... Agent: Ropes & Gray LLP

20090192082 - Cxcr4 antagonist treatment of hematopoietic cells: Compositions comprising a peptide consisting of an amino acid sequence derived from a P2G-substituted SDF-1 protein are taught. The amino acid sequence consists of a first sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif. The amino... Agent: Tips Group C/o Intellevate LLC

20090192085 - Fkbp-l and uses thereof: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.... Agent: Kilpatrick Stockton LLP

20090192086 - Identification of a novel bhd gene: The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating... Agent: Klarquist Sparkman, LLP

20090192083 - Methods and compositions for the treatment of gastrointestinal disorders: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and... Agent: Honigman Miller Schwartz & Cohn LLP

20090192087 - Methods and compositions using klotho-fgf fusion polypeptides: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. The Klotho fusion proteins are useful in the treatment and prevention of a... Agent: Novartis Institutes For Biomedical Research, Inc.

20090192088 - Vascular endothelial growth factor 2: Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Such polypeptides may be combined with a suitable pharmaceutical carrier or diluent to provide diagnostic, therapeutic and/or prophylactic effects... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090192090 - Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity: The invention provides compounds having immune-modulating and/or anti-inflammatory and/or anti-viral activity, wherein compounds of the invention include peptides and peptidomimetics. The invention further provides methods of using immune-modulating and/or anti-inflammatory and/or anti-viral compounds of the invention. In particular, the invention provides methods for treating a disease related to an immune... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090192089 - Peptides for activation and inhibition of deltapkc: Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as... Agent: Morrison & Foerster LLP

20090192091 - Peptide inhibitors of protein kinase c: PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.... Agent: King & Spalding LLP

20090192092 - Neuropeptides and their use for pest control: The present invention discloses novel pest control compounds comprising NPF polypeptides and methods for using such compounds in the control of pests.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090192093 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090192094 - Treatment of diseases using ice inhibitors: This invention relates to methods and compositions for treating autoinflammatory diseases. The invention also assays for evaluating the ability of an ICE inhibitor to treat autoinflammatory diseases.... Agent: Ropes & Gray LLP

20090192096 - 2'-substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them: i

20090192095 - Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects: The present invention relates to methods for reducing gastrointestinal side effects in a subject, the gastrointestinal side effects being associated with the administration of an opioid analgesic. The methods comprise orally administering an opioid prodrug or pharmaceutically acceptable salt thereof to a subject, wherein the opioid prodrug is comprised of... Agent: Darby & Darby P.C.

20090192097 - Synergistic herbal composition from bacopa species for management of neurodegenerative disorders and a process of preparation thereof: The present invention relates to a potent synergistic herbal composition [BacoMind®] from the plant species Bacopa monnieri and its beneficial effects in learning, memory, cognition and Attention Deficit Hyperactivity Disorder [ADHD] or Attention Deficit Disorder [ADD]. In addition, the present invention provides the synergistic composition derived from Bacopa monnieri such... Agent: Harness, Dickey & Pierce, P.L.C

20090192098 - Method for treating hematopoietic neoplasms: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive... Agent: Oxigene, Inc. C/o Law Offices Of Karen E. Flick

20090192099 - Prodrugs of heteroaryl compounds: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.... Agent: Townsend And Townsend And Crew, LLP

20090192107 - Breast cancer markers: A method for the detection of the presence of or the risk of cancer in a patient, comprising, with reference to a normal control, the step of: (i) detecting the expression level of a gene characterised by any of the nucleotide sequences identified herein as SEQ ID No. 1 to... Agent: Oliff & Berridge, PLC

20090192101 - Cancer-specific promoters: The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-specific and ovarian cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of fatty acid synthase and claudin 4 promoters, particularly... Agent: Fulbright & Jaworski, LLP

20090192117 - Compositions and methods for the suppression of target polynucleotides from lygus: Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the Lygus genus, they are capable of decreasing the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls... Agent: Alston & Bird LLP Pioneer Hi-bred International, Inc.

20090192116 - Compositions and methods for the suppression of target polynucleotides from the family aphididae: Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the Aphididae family, they are capable of decreasing the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls... Agent: Alston & Bird LLP Pioneer Hi-bred International, Inc.

20090192112 - Compositions and methods for treating cancer: The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target ATDC (TRIM29) expression in cancer with ATDC overexpression.... Agent: Casimir Jones, S.c.

20090192109 - Compositions for diagnosis and therapy of diseases associated with aberrant expression of kremen and/or wnt: The present invention relates to a composition useful for the diagnosis and therapy of diseases associated with aberrant expression of the gene encoding the receptor Kremen 1 and/or Kremen 2 e.g. tumors or diseases of the kidneys, bones and eyes, lipid and glucose metabolism and obesity. The present invention also... Agent: Klauber & Jackson

20090192108 - Gene overexpressed in cancer: Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide... Agent: Davidson, Davidson & Kappel, LLC

20090192113 - Interfering rna duplex having blunt-ends and 3`-modifications: s

20090192114 - Mir-10 regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-10, using miR-10 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fullbright & Jaworski L.L.P.

20090192111 - Mir-124 regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-124, using miR-124 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fullbright & Jaworski L.L.P.

20090192102 - Mir-21 regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-21, using miR-21 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fullbright & Jaworski L.L.P.

20090192106 - Modulation of eif4e expression: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with... Agent: Eli Lilly & Company

20090192103 - Multitargeting interfering rnas having two active strands and methods for their design and use: Interfering RNA molecules are now designed and produced with specificity for multiple binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules and are used to modulate expression of the target sequences. The multitargeting interfering RNA molecules have two strands that target multiple target sites... Agent: Crowell & Moring LLP Intellectual Property Group

20090192100 - Novel use of spiegelmers: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.... Agent: Mdip LLC

20090192110 - Rna antagonist compounds for the modulation of pik3ca expression: The present invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for... Agent: Dechert LLP

20090192104 - Rna interference mediated inhibition of hypoxia inducible factor 1 (hif1) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating hypoxia inducible factor (e.g., HIF1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of HIF1 gene... Agent: Sirna Therapeutics, Inc.

20090192105 - Rna interference mediated inhibition of intercellular adhesion molecule (icam) gene expression using short interfering nucelic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ICAM gene expression... Agent: Sirna Therapeutics, Inc.

20090192118 - Tak1-d mediated induction of cell death in human cancer cells by specific sequence short double-stranded rnas: The splicing variant D of the TAK1 gene is activated by short double-stranded RNAs in a sequence specific manner. Activation of TAK1-D leads to the downstream activation of the p38 MAPK and of SAPK/JNK but not the NFκB pathway. The current invention therefore provides a method of inducing apoptosis and/or... Agent: Fulbright & Jaworski L.L.P.

20090192115 - Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization: The use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization. Particularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).... Agent: Young & Thompson

20090192119 - Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology: A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090192120 - Inhibitors of nitric oxide synthase: The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of... Agent: Fulbright & Jaworski L.L.P.

20090192121 - Novel bisamidate phosphonate prodrugs: e

20090192122 - Inflammatory cytokine release inhibitor:

20090192123 - Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors: A method of treatment of the human or non-human animal body for treating or preventing disorders caused by elevated thrombin or elevated thrombin receptor expression is disclosed, for example thromboembolic disease vascular syndromes, or proliferative diseases, which method comprises administering to a human or non-human animal body in need of... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090192125 - Local anti-infective agent for treatment of nail fungal infections: A topical composition for treating nail fungal infections that utilizes an acidic antifungal agent with a molecular weight no greater than 170 Daltons in a formulation having a pH less than or equal to the pKa of the acidic antifungal agent plus one. Possible antifungal agents include omadine, octanoic acid,... Agent: Ropes & Gray LLP

20090192124 - Use of ceramides for depigmenting the skin: t

20090192126 - Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin: A composition which is adapted for oral consumption and which is in the form of a substantially homogeneous aqueous emulsion, suspension or dispersion comprising salicylic acid, or a C1 to C6 alkyl ester thereof, and docosahexaenoic acid (DHA) can exhibit an anti-inflammatory effect in skin.... Agent: Unilever Patent Group

20090192129 - Bicyclic pyrrole derivatives: c

20090192127 - Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment: The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound e.g. 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and an PI3K/AKT signaling pathway inhibitor The PI3K/AKI signaling pathway inhibitor comprises PI3 inhibitors {like celecoxilo, viridins, wortmannins}, AKT kinase inhibitors {like perifosine, triciribine} and mTOR inhibitors {like the... Agent: Barbara A. Shimei Director, Patents & Licensing

20090192128 - Genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism: The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance;... Agent: Wilmerhale/nitromed

20090192130 - Method for treating uterine fibroids: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090192131 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090192132 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20090192133 - Treatment for achondroplasia: The present application provides, inter alia, methods of treating disorders mediated by FGFRs and methods of screening for Hsp90 inhibitor compounds.... Agent: Fish & Richardson PC

20090192135 - Human niemann pick c1-like 1 gene (npc1l1) polymorphisms and methods of use thereof: The present invention relates to the identification and use of single nucleotide polymorphisms and haplotypes in the Niemann Pick C1-Like 1 (NPC1L1) gene. In particular, methods are provided for correlating NPC1L1 polymorphisms and haplo-types with the responsiveness of a pharmaceutically active compound administered to a human subject. The invention further... Agent: Foley And Lardner LLP Suite 500

20090192137 - Dialysis method: There is provided the use of a low molecular weight thrombin inhibitor for the manufacture of a medicament for the treatment by dialysis, particularly haemodialysis, of a patient in need of such treatment, in which the thrombin inhibitor is provided in the dialysing solution, as well as dialysing solutions and... Agent: Nixon & Vanderhye, PC

20090192136 - Benzoyl-piperazine derivatives: e

20090192134 - Compounds: A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof: and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.... Agent: Morgan Lewis & Bockius LLP

20090192138 - compounds: The invention provides novel deazaxanthine and deazahypoxanthine compounds. The compounds may be useful in the therapy of diseases and conditions in which dipeptidylpeptidase-IV (DPP-IV) is implicated.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090192139 - Cgrp receptor antagonists: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.... Agent: Merck And Co., Inc

20090192140 - Iap bir domain binding compounds: h

20090192141 - Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.... Agent: Paul D. Yasger Abbott Laboratories

20090192142 - Use of carbamazepine derivatives for the treatment of agitation in dementia patients: The present invention relates to the use of a compound of formula (I) wherein R1 and R2 together form an oxo group, or a pharmaceutically acceptable salt thereof, for the treatment of agitation, in particular behavioral agitation, especially in dementia patients diagnosed with Alzheimer's disease; pharmaceutical compositions comprising a compound... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090192143 - Substituted diazepan orexin receptor antagonists: The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20090192144 - Imidazo compounds: The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof in which R, R1, R2, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090192145 - Spiro-imidazo compounds: Novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R1, R1′, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090192146 - Substituted organosulfur compounds and methods of using thereof: The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions.... Agent: Morrison & Foerster LLP

20090192147 - [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses: e

20090192149 - Imidazo compounds: The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R1, R2, Q, m and n have the meanings explained in detail in the description and * designates an asymmetric carbon atom, a process for their preparation and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090192150 - Imino-imidazo-pyridine derivatives having antithrombotic activity: e

20090192148 - Organic compounds:

20090192151 - Therapeutic amides and related compounds: Disclosed herein are compounds useful in treating glaucoma, inflammatory bowel disease, the stimulation of hair growth, and the stimulation of the conversion of vellus hair to terminal hair. The compounds themselves are herein.... Agent: Allergan, Inc.

20090192152 - Novel antigiardial agents and methods of use thereof: The present invention provides a method of preventing or treating one or more of the following medical conditions, or treating symptoms of one or more of the following medical conditions: amebic infections, giardiasis, estrogen deficient states, osteoporosis, cardiovascular heart disease, high cholesterol levels, hyperlipidemia, cancer by administering to a subject... Agent: Stites & Harbison PLLC

20090192153 - Novel adenine compound: wherein R1 is optionally substituted alkyl group, etc., X is oxygen atom, etc., A is 4 to 8 membered optionally substituted saturated or unsaturated heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom and 0 to 1 sulfur atom,... Agent: Birch Stewart Kolasch & Birch

20090192154 - Sultam derivatives: A sultam derivative of Formula (1) described below having inhibitory action for aggrecanase activity is provided. The sultam derivative of Formula (1) and a salt thereof exhibit strong inhibitory action for aggrecanase activity in a living body of a mammalian animal including human, and is useful, for example, as an... Agent: Birch Stewart Kolasch & Birch

20090192155 - Identification of compounds suitable for treating ad: The invention provides a method of screening for compounds which inhibit the hyperphosphorylation of tau, and hence are suitable for treating AD and related conditions.... Agent: Merck And Co., Inc

20090192156 - Phthalazinone derivatives: A and B together represent an optionally substituted, fused aromatic ring; X and Y are selected from CH and CH, CF and CH, CH and CF and N and CH respectively; RC is selected from H, C1-4 alkyl; and R1 is selected from C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl,... Agent: Morgan Lewis & Bockius LLP

20090192157 - Indole compounds and methods for treating visceral pain: The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I),... Agent: Clark & Elbing LLP

20090192158 - Methods for treating or preventing neoplasias: The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia.... Agent: Merck And Co., Inc

20090192159 - Substituted gamma lactams as therapeutic agents: e

20090192160 - Compounds:

20090192161 - Amorphous and crystalline forms of aprepitant and processes for the preparation thereof: An amorphous form of aprepitant and a process for its preparation is provided. Also provided are mixtures of polymorph Forms I and II of aprepitant and a process for the preparation thereof.... Agent: M. Carmen & Associates, PLLC

20090192162 - Phenoxy acetic acids as ppar delta activators: The present invention describes phenoxy-acetic acids and pharmaceutical compositions containing the same and methods of using the same. The phenoxy-acetic acids are activators of PPAR-δ and should be useful for treating conditions mediated by the same.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090192163 - Novel compounds: The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent: Fish & Richardson P.C.

20090192165 - Antimicrobial solutions and process related thereto: Disclosed are antimicrobial compositions for treating poultry and meat to substantially eliminate bacteria and microorganism harmful to human. The compositions include various combinations of an aliphatic heteroaryl salt, an aliphatic benzylalkyl ammonium salt, a dialiphatic dialkyl ammonium salt, a tetraalkyl ammonium salt and/or trichloromelamine.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090192164 - Treating agent of inflammatory bowel disease: The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090192166 - Method for augmenting the effects of serotonin reuptake inhibitors: A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enhancer,... Agent: Myers Bigel Sibley & Sajovec

20090192167 - Insecticidal and fungicidal composition: wherein, in the formula, A1, A2, A3, and A4 independently represent a carbon atom, a nitrogen atom or an oxidized nitrogen atom; G1 and G2 independently represent an oxygen atom or a sulfur atom; R1 and R2 independently a hydrogen atom or a C1-C4 alkyl group; Xs may be the... Agent: Buchanan, Ingersoll & Rooney PC

20090192168 - Compounds, compositions and methods: Certain substituted urea derivatives modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090192169 - Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090192170 - Furo[3,2-b] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof (I), wherein: R3 is cyclopentyl or cyclohexyl; X is CH or N; and R4 is optionally substituted C1-8 alkyl or optionally substituted C3-8 cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I),... Agent: Edwards Angell Palmer & Dodge LLP

20090192171 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20090192172 - 2-alkyl-cycloalk(en)yl-carboxamides: s

20090192173 - Anti-tubercular drugs: compositions and methods: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.... Agent: King & Spalding

20090192174 - Novel aminopyridine derivatives having aurora a selective inhibitory action: t

20090192175 - Insecticidal compounds: Novel heteroaromatic compounds of formula (I): wherein A1, A2, A3, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them... Agent: Syngenta Crop Protection, Inc., Patent And Trademark Department

20090192176 - 1h-pyrazolo[3,4-d]pyrimidine, purine, 7h-purin-8(9h)-one, 3h-[1,2,3]triazolo[4,5-d]pyrimidine, and thieno[3,2-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses: The invention relates to 1H-pyrazolo[3,4-d]pyrimidine, purine, 7H-purin-8(9H)-one, 3H-[1,2,3]triazolo[4,5-d]pyrimidine, and thieno[3,2-d]pyrimidine compounds, compositions comprising the compounds, and methods for making and using the compounds.... Agent: Wyeth Patent Law Group

20090192177 - 2-aryl pyrrologpyrimidines for a1 and a3 receptors: This invention pertains to compounds which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.... Agent: Cooper & Dunham, LLP

20090192178 - Mglur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090192179 - Chroman derivatives: wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondria) disorders. They are also useful in the manufacture of pharmaceutical... Agent: Morrison & Foerster LLP

20090192180 - Alpha-7 nicotinic receptor agonists and statins in combination: Combinations of α7-nAChR agonists and statins, pharmaceutical compositions containing the same and methods of using the same useful for treatment or prophylaxis of neurological degenerative diseases.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090192181 - Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,... Agent: Foley & Lardner LLP

20090192182 - Compound having acidic group which may be protected, and use thereof: a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for... Agent: Sughrue-265550

20090192183 - Oxymorphone controlled release formulations: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.... Agent: Mayer Brown LLP

20090192184 - Crystalline polymorphs of topotecan hydrochloride and methods for the preparation thereof: e

20090192185 - Medical product: The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ingress of moisture into... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090192186 - Biaryl substituted azabicyclic alkane derivatives: The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20090192187 - Dry powder formulation comprising an anticholinergic drug: Pharmaceutical formulation in the form of inhalable dry powder comprising particles of a pharmaceutically acceptable salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane as active ingredient, and particles of a carrier made of a physiologically acceptable pharmacologically-inert material are effective for the prevention and/or treatment of a respiratory disease such as asthma and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090192188 - Tetrahydroisoquinoline derivatives: This invention relates to novel tetrahydroisoquinoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual OX-1/OX-2 orexin antagonist.... Agent: Kenyon & Kenyon LLP

20090192189 - Treatment of cancers expressing p95 erbb2: The truncated ErbB2 receptor (p95ErbB2) is shown to differ from the full-length ErbB2 receptor in its association with other ErbB receptors. The truncated receptor preferentially associated with ErbB3, whereas full length ErbB2 heterodimerizes with either EGFR or ErbB3. Consistent with p95ErbB2 heterodimerization with ErbB3, it is shown that heregulin (an... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090192190 - Benzoic acid derivatives that are modulators or agonists of glyr: e

20090192191 - Substituted hydroxamic acid derivatives as tnf inhibitors: The present invention relates to novel compounds of formula (I) and their pharmaceutically useful compositions as MMP and TNF inhibitors.... Agent: Nixon & Vanderhye, PC

20090192192 - Inhibitors of biofilm formation of gram-positive and gram-negative bacteria: The present invention relates to the use of compounds as broad spectrum inhibitors of bacterial biofilm formation. In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative and Gram-positive bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their... Agent: Davis Wright Tremaine LLP - San Francisco

20090192193 - Diagnostic agent and method for detection of cancer and a means for treatment of same: A method is disclosed for detecting colorectal carcinoma having at least one HERG potassium ion channel, where at least one HERG potassium channel is detected in a tissue biopsy of the human color or rectum. In addition, a method is disclosed for treating colorectal carcinoma having at least one HERG... Agent: K.f. Ross P.C.

20090192194 - Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them: m

20090192195 - Compounds having crth2 antagonist activity:

20090192196 - Fungicide hydroximoyl-tetrazole derivatives: The present invention relates to hydroximoyl-tetrazole derivatives of formula (I) wherein T represent a tetrazolyl substituent, A represents a carbo- or heterocycle, L1 and L2 represent various linking groups and Q represents a 6-membered heterocycle, their process of preparation, their use as fungicide active agents, particularly in the form of... Agent: Ostrolenk Faber Gerb & Soffen

20090192197 - Novel oxazolidinone derivatives: The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having... Agent: Knobbe Martens Olson & Bear LLP

20090192198 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.... Agent: Paul D. Yasger Abbott Laboratories

20090192199 - Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression: Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists. to enhance brain neurotrophism.... Agent: Townsend And Townsend And Crew, LLP

20090192200 - Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof: Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof.... Agent: Kenyon & Kenyon LLP

20090192201 - Composition and method for treating and preventing musculoskeletal and connective tissue disorders: The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected... Agent: Yamil E Selman

20090192202 - Androgen modulators: The present invention is directed to a new class of 4-cyano-phenoxy-alkyl carboxyl derivatives and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.... Agent: Pfizer Inc. Patent Department

20090192203 - Compounds and compositions as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.... Agent: Genomics Institute Of The Novartis Research Foundation

20090192204 - N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.... Agent: Hoffmann & Baron, LLP

20090192205 - Process for release of biologically active species: providing said ordered mesoporous oxide with said fixed or immobilized biologically active species in vivo thereby realizing intraluminally induced substantially pH-independent supersaturation of said biologically active species resulting in enhanced transepithelial transport; wherein said biologically active species is a poorly soluble therapeutic drug classified as belonging to Class II or... Agent: Clark & Elbing LLP

20090192206 - Mercaptoimidazoles as ccr2 receptor antagonists: o

20090192207 - Topical formulations comprising 1-n-arylpyrazole derivatives and amitraz: The present invention provides for, inter alia, novel topical formulations comprising at least one 1-N-arypyrazole derivative and amitraz and to methods for treating, controlling, or preventing parasite infestations on mammals or birds The inventive formulations include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an... Agent: Frommer Lawrence & Haug

20090192208 - Pyrazole compounds and use thereof in noxious arthropod pests controlling composition: The present invention provides a pyrazole compound of formula (a): a noxious arthropod pests controlling composition containing the compound shown by the formula (a) as an active ingredient; and a method for controlling noxious arthropod pests comprising applying an effective amount of the compound shown by the formula (a).... Agent: Birch Stewart Kolasch & Birch

20090192209 - Extended treatment of tumors through vessel occlusion with light activated drugs: Methods of treating diseases of a subject through selective occlusion of blood vessels. The methods include identifying and/or mapping the blood vessels supplying nutrients to the diseased or unwanted tissue, delivering an appropriate dose of an occlusion-forming photosensitizer to the subject, and exciting the photosensitizer with sufficient light irradiation in... Agent: Seed Intellectual Property Law Group PLLC

20090192211 - Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination: The invention relates to a combination which comprises (a) a cyclooxygenase-2 inhibitor (“COX-2 inhibitor”) and (b) a histone deacetylase inhibitor (“HDAI”) for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of pre-malignant colon lesions or a colon cancer or other malignancies in a mammal, particularly a... Agent: Novartis Corporate Intellectual Property

20090192210 - Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide: Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide free base and salts thereof are prepared by various processes.... Agent: Novartis Corporate Intellectual Property

20090192212 - Dithiol compounds, derivatives, and uses therefor: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.... Agent: Townsend And Townsend And Crew, LLP

20090192213 - Benzo[b]furane and benzo[b]thiophene derivatives: The present invention relates to benzo[b]furane and benzo[b]thiophene derivatives of the general formula IV as the free base or salts thereof and their use.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20090192214 - Drug delivery from rapid gelling polymer composition: Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For... Agent: Seed Intellectual Property Law Group PLLC

20090192215 - Cytotoxin compounds and methods of isolation: The present invention concerns groups of compounds derived from tunicates of the Synoicum species, as well as to pharmaceutical compositions comprising these compounds, and uses thereof. Extracts from tunicates show selective toxicity against several different cancer cell lines in the NCI 60 cell line panel. These compounds are useful in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090192216 - Methods for the formulation and manufacture of artesunic acid for injection: A method for the manufacture of a sterile intravenous or intramuscular formulation of artesunic acid and the formulation are the subject of this invention. First the artesunic acid powder is sterilized with ethylene oxide and placed into a sterile container. The contained sterilized powder is then dissolved in sterile sodium... Agent: Caroline Nash Nash & Titus, LLC

20090192217 - Method and composition for treating acne using lignan compounds: The present invention relates to a method and composition for treating acne using lignan compounds represented by Formula 1. More particularly, the invention relates to an antibacterial composition against acne-causing bacteria, containing lignan compounds represented by Formula 1, as well as a method for treating acne using the same. The... Agent: Jhk Law

20090192218 - Use of phthalide derivatives for the treatment and prevention of diabetes mellitus: The present invention relates to the use of a compound as effective agent for the prevention or treatment of diabetes mellitus in a mammal. Said compounds being selected from the group of phthalide derivatives and exhibit excellent blood glucose lowering effects and thus are effective agents in the prevention or... Agent: Hoxie & Associates LLC

20090192219 - Stabilization of iodine-containing biocides by means of special azole compounds: Specific azole compounds are outstandingly suitable for stabilizing iodine-containing biocides in industrial materials, more particularly in paints based on alkyd resin.... Agent: Lanxess Corporation

20090192220 - Treatment for solid tumors: A method for treating a solid tumor in a subject comprises administering to the subject an ACAT inhibitory compound or a prodrug thereof, for example avasimibe, wherein (a) the solid tumor is at least about 2 mm in diameter and (b) the compound or prodrug thereof is administered in an... Agent: Harness, Dickey, & Pierce, P.l.c

20090192221 - Carbamate antibiotics: The invention relates to the field of antibiotic compositions, both inside and outside the medical field. Presented is a new class of antibiotic compounds around the lead compound (3,4-dichloro-phenyl)-carbamic acid 2-isobutoxycarbonylamino-1-methyl-ethyl ester, which are especially useful for combating infections with gram-positive bacteria and especially MRSA.... Agent: Lucas & Mercanti, LLP

20090192222 - Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use: Mesophasic forms of (3S)-aminomethyl-5-hexanoic acid prodrugs and methods of preparing and methods of using mesophasic forms of (3S)-aminomethyl-5-hexanoic acid prodrugs are provided.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090192224 - Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof: The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite,... Agent: Kenyon & Kenyon LLP

20090192223 - Gip secretion inhibitor: The object of the invention is to provide a GIP secretion inhibitor which is a useful drug or food ingredient. The present invention provides an agent for inhibiting postprandial GIP secretion contains a monoacylglycerol as an active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090192225 - Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use: Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharmaceutical compositions thereof to treat a disease are disclosed. Acyloxyalkyl carbamate prodrugs of α-amino acids suitable for oral administration using sustained... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090192226 - Materials and methods for treatment of pathological ocular vascular proliferation: The subject invention provides for the administration of docosahexaenoic acid in preventing pathological proliferation of blood vessels. The compositions of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090192227 - N-acetylcysteine compositions and methods for treating acute exacerbations of inflammatory lung disease: The present invention relates to N-acetylcysteine compositions and methods for treating inflammation and redox imbalance in acute exacerbations of inflammatory lung disease.... Agent: Greenberg Traurig, LLP

20090192228 - Controlled-release tolterodine compositions and methods: Controlled-release tolterodine compositions, including controlled-release particles, pellets, granules, and spheres, comprising an inert core, a first layer disposed on the inert core, and a second layer disposed on the first layer are described. Methods for preparing such compositions and methods of treating a variety of disorders are also disclosed.... Agent: Cantor Colburn, LLP

20090192229 - 2-aminoalcohols for the treatment of neurodegenerative diseases: Use of a compound for the manufacture of a medicament for use in therapy of a neurodegenerative condition, wherein the compound is of formula (I): wherein R1 is CHR4—OR5 or CHR4—SR5, or aryl or heteroaryi optionally substituted with one or more groups R6; R2 is alkyl or is part of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090192230 - Propofol-containing fat emulsion preparation: The present invention provides a propofol-containing fat emulsion that can be administered with reduced vascular pain without incorporating a local anesthetic such as lidocaine; and a process for producing the same. The fat emulsion comprises 0.1 to 5 w/v % of propofol, 2 to 20 w/v % of an oily... Agent: Sughrue Mion, PLLC

20090192231 - Antimicrobial compositions and methods of use thereof: The invention provides antimicrobial compositions comprising one or more acid and one or more organic diol. In one embodiment, the invention's compositions have an acidic pH. The compositions may optionally further contain one or more oxidizing agent (including stabilized oxidizing agent and/or unstabilized oxidizing agent), and/or one or more surfactant.... Agent: Peter G. Carroll Medlen & Carroll, LLP

20090192232 - Supplementary food composition for reducing body odor: This invention relates to a food supplement for reducing body odor; it is a mixture of edible carriers with chitin aqueous solution lyophilized powder, chitosan aqueous solution lyophilized powder, chitin powder, chitosan powder, or the composition of these ingredients, and it comes in the form of tablets or pills. The... Agent: Birch Stewart Kolasch & Birch

20090192233 - Cosmetic or pharmaceutical preparation: The invention proposes a cosmetic or pharmaceutical preparation containing a mixture of medium-chain, preferably saturated triglycerides with a fatty acid chain length of between C8 and C10 of between 60% and 98% and a content of saturated, long-chain, preferably saturated triglycerides with a fatty acid chain length of between C18... Agent: Ursula B. Day, Esq.

  
07/23/2009 > patent applications in patent subcategories. category listing

20090186804 - Anticoagulant and composition for preventing thrombus containing poly-gamma-glutamic acid: The present invention relates to an anticoagulant and a composition for preventing thrombus formation, which contain poly-gamma-glutamic acid (PGA) as an active ingredient. The inventive PGA is a water-soluble, anionic, biodegradable and edible amino acid polymer material, which has an anticoagulant effect of preventing thrombi from being accumulated in blood... Agent: Moore & Van Allen PLLC

20090186802 - Cell penetrating peptide conjugates for delivering of nucleic acids into a cell: The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions,... Agent: Hunton & Williams LLP Intellectual Property Department

20090186805 - Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance: Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as... Agent: Kilpatrick Stockton LLP

20090186801 - Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells: The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and... Agent: K&l Gates LLP

20090186806 - Truncated activin type ii receptor and methods of use: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper LLP (us)

20090186803 - Use of nutritional compositions with phospholipid, sphingolipid and cholesterol.: A nutritional composition comprising phospholipids, sphingolipids and cholesterol for the prevention of obesity and/or diabetes is provided.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090186807 - Zinc-free and low-zinc insulin preparations having improved stability: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090186808 - Method and compound for the treatment of valvular disease: A method for treating valvular stenosis The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal Most preferred is an Apolipoprotein A-1 mimetic peptide/phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ... Agent: Tessier & Assocaies Inc C P 54029

20090186809 - Use of valproic acid for the topical treatment of mild to moderate acne vulgaris: The present invention provides a surprising therapeutic beneficial use for the topical application of valproic acid as a single agent therapy for patients suffering from mild to moderate acne vulgaris. Topically applied VPA has a clinical efficacy comparable to that of the marketed standard medication for this indication, isotretinoin. Furthermore,... Agent: Cermak Kenealy Vaidya & Nakajima LLP

20090186810 - Potassium channel modulators and platelet procoagulant activity: Methods of modulating platelet procoagulant response are taught herein. Inhibition of platelet procoagulant response with agents that inhibit the Ca2+-sensitive K+ channels, or Gardos channels, preferably while maintaining platelet bleeding arrest function, may be used to treat a variety of disorders.... Agent: Foley & Lardner LLP

20090186812 - Apo-2 ligand: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand... Agent: Genentech, Inc.

20090186813 - Chronic treatment regimen using glucagon-like insulinotropic peptides: The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.... Agent: Eli Lilly & Company

20090186819 - Formulation of insulinotropic peptide conjugates: The present invention provides pharmaceutical formulations comprising insulinotropic peptide conjugates, particularly a conjugate of albumin to exendin-4, or a derivative thereof, and methods of administration thereof. The present invention also provides methods for treating diabetes and insulinotropic peptides related diseases or conditions by administering the pharmaceutical formulations described herein.... Agent: Jones Day

20090186815 - Identification of jak/stat pathway modulating genes by genome wide rnai screening: The present invention relates to a method for identifying a compound capable of modulating the activity of the JAK/STAT pathway and to the use of different JAK/STAT pathway components as a target for the modulation of the activity of the JAK/STAT pathway. Moreover, the present invention is concerned with a... Agent: Millen, White, Zelano & Branigan, P.C.

20090186814 - Methods and compositions for reducing ischemia-derived microvascular damage: Methods of decreasing the extent of occlusion in the lumen of a mammalian blood vessel due to an ischemic or other hypoxic event are provided. In one form, a method includes administering to a patient in need thereof a pharmaceutically effective amount of an inhibitor of δ protein kinase C,... Agent: Perkins Coie LLP

20090186817 - Peptide-peptidase inhibitor conjugates and methods of using same: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090186816 - Polypeptide targeting to mitochondria: Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a DNA-binding polypeptide, fused to a mitochondrial targeting sequence (MTS) and a nuclear export signal (NES), and the encoded proteins. The construct successfully delivers DNA binding proteins to the mitochondrion.... Agent: Frommer Lawrence & Haug

20090186820 - Streptococcus pyogenes polypeptides and corresponding dna fragments: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.... Agent: Seed Intellectual Property Law Group PLLC

20090186818 - Therapeutic method for glycaemic control: The invention relates to a therapeutic method for glycaemic control, comprising the use of a combination of a DPIV inhibitor and a GLP-1 receptor agonist.... Agent: Osi Pharmaceuticals, Inc.

20090186822 - Thrombopoietic compounds: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.... Agent: Marshall, Gerstein & Borun LLP

20090186821 - Use of aspartic proteases in cosmetics and therapeutics: The invention provides a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one purified natural or synthetic polypeptide wherein the peptide sequence is represented wholly or partly by at least one sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 4,... Agent: Buchanan, Ingersoll & Rooney PC

20090186811 - Y2 selective receptor agonists for therapeutic interventions: Y receptor agonists other than PYY 3-36, which are selective for the Y2 receptor over the Y1 and Y4 receptors, and their use in the treatment of conditions responsive to activation of Y2 receptors, are disclosed. Broadly, a Y2-selective agonist is one which (a) is a PP-fold peptide or PP-fold... Agent: Banner & Witcoff, Ltd.

20090186823 - Synthetic arginine substituted peptides and their use: The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars.... Agent: Buchanan, Ingersoll & Rooney PC

20090186824 - Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity: In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition... Agent: Mccarthy Tetrault LLP

20090186825 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090186826 - Cosmetic or dermopharmaceutical compositions of ceramides and polypeptides: Personal care products including cosmetics, grooming products and topical pharmaceutical products can be produced including a polypeptide of between 3 and 12 amino acids in length and a ceramide. These formulations are particularly useful in addressing wrinkles in human subjects and in particular facial skin and hands. Certain analogs and... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090186828 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090186829 - Nitrosation-inducible inhibitors biological macromolecules: e

20090186827 - Process of inhibiting cell death in injured cartilage: Processes for inhibiting apoptotic cell death and glycosaminoglycan release from injured cartilage is provided. Inhibition is accomplished using caspase inhibitors.... Agent: The Scripps Research Institute

20090186832 - Amino acid peptide pro-drugs of phenolic analgesics and uses thereof: Prodrugs of meptazinol and other phenolic analgesics exhibiting low oral bioavailability with amino acids or lower peptides, pharmaceutical compositions containing such prodrugs and a method for providing pain relief with such prodrugs are provided. In addition, the present invention relates to methods for increasing the oral bioavailability of a phenolic... Agent: Darby & Darby P.C.

20090186830 - Macrocycles and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090186831 - Tetrahydrofuro(3,2-b) pyrrol-3-one derivatives as inhibitors of cysteine proteinases: The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as... Agent: Edwards Angell Palmer & Dodge LLP

20090186833 - Method for producing pectin hydrolysis products: Methods for the production of pectin hydrolysis products, the pectin hydrolysis products produced in this manner, as well as their use are described.... Agent: Dickstein Shapiro LLP

20090186834 - Diphenylheterocycle cholesterol absorption inhibitors: Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090186836 - Method for neutralizing fungi using sophorolipids and antifungal sophorolipids for use therein: 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octa-decenoate, lactonic and open ring 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, methyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, hexyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6″-acetate and ethyl 17-L-[(2′-O-β-D-glucopyranosyl-β-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6′,6″-diacetate sophorolipids and uses thereof as antifungal agents.... Agent: Smith, Gambrell & Russell

20090186835 - Treatment and prophylaxis of cancer: A method and composition for the prophylaxis or treatment of humans or animals for cancer using a mixture of sophorolipids.... Agent: Smith, Gambrell & Russell

20090186837 - Anti-neoplastic compositions comprising extracts of black cohosh: A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination,... Agent: Kevin C. Hooper Bryan Cave LLP

20090186838 - Amphotericin derivatives: The present invention provides new polyene macrolide derivatives which show very low toxicity while retaining high antifungal activity as compared with amphotericin B (AmB). These polyene macrolide derivatives comprise a polyene macrolide backbone having at least one free amino group, wherein the amino group is doubly alkylated with at least... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090186839 - Model for studying the role of genes in chemoresistance: The invention provides novel inhibitors of protein translation initiation and inhibitors of eIF4F activity that can increase chemosensitivity or diminish or reverse chemoresistance in growth transformed cells and thereby reduce hyperproliferative conditions, such as cancer progression, in select patient populations having particular tumor genotypes. The invention also provides methods which... Agent: Wilmerhale/cold Spring Harbor Laboratory

20090186840 - 5-thioxylopyranose compounds: Compounds of 5-thioxylopyranose, preferably derivatives of the 5-thioxilopyranose type, a method for preparing such compounds, and the use of such compounds as an active ingredient in pharmaceutical compositions which are useful, in particular, for treating or inhibiting thrombosis or heart failure or thromboembolic disease states.... Agent: Crowell & Moring LLP Intellectual Property Group

20090186841 - Novel aminoglycoside antibiotics: This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090186847 - Antisense antiviral compounds and methods for treating a filovirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg... Agent: King & Spalding LLP

20090186848 - Antisense antiviral compounds and methods for treating a filovirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg... Agent: King & Spalding LLP

20090186849 - Antisense antiviral compounds and methods for treating a filovirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg... Agent: King & Spalding LLP

20090186845 - Interfering rna molecules: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090186842 - Methods and compositions for inhibition of viral replication: The present invention is directed to methods and compositions that are effective in the inhibition of viral replication. In particular, the methods and compositions are effective at interfering with the activity of host cell proteins required in viral replication. For example, an embodiment of the invention is directed to methods... Agent: Troutman Sanders LLP Bank Of America Plaza

20090186846 - Methods to reprogram splice site selection in pre-messenger rnas: The present invention relates to a method of modulating splice site selection, splicing and alternative, the method comprising the step of hybridizing an oligonucleotide-protein conjugate to a target pre-mRNA molecule in a cell or cell extract, wherein the oligonucleotide-protein conjugate comprises an oligonucleotide moiety which comprises at least two distinct... Agent: Klauber & Jackson

20090186843 - Rna sequence-specific mediators of rna interference: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long... Agent: Wolf Greenfield & Sacks, P.C.

20090186844 - Sirna delivery into mammalian nerve cells: The present invention relates to methods of affecting expression of a target gene, suitably brain-derived neurotrophic factor (BDNF) or related genes in a nerve cell in the central nervous system of a mammal. The method includes formulating and delivering an siRNA composition to a target site on the mammal to... Agent: Quarles & Brady LLP

20090186850 - Peritoneal dialysis method: e

20090186851 - Hemostatic material: A hemostatic powder comprises a chitosan salt together with at least one inert material. The disclosure also relates to hemostatic powders into which fluid penetrability is 0.5 cm or more within 1 minute. At least one medical surfactant may optionally be included. The hemostatic powders may be incorporated into wound... Agent: Barlow, Josephs & Holmes, Ltd.

20090186852 - Tri- and tetra-oligo-saccharides suitable as agglutination agents for enteric pathogens: Compositions which include a homotrimer, heterotrimer, homotetramer, and/or heterotetramer of a component such as pentose, hexose, an L or D isomer of a pentose or hexose, a β-form of a pentose or hexose, oxidized derivatives and mixtures of such compounds are disclosed as agglutination agents. The disclosed compositions are useful... Agent: Knobbe Martens Olson & Bear LLP

20090186853 - Compositions comprising n-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof: The embodiments relate to compositions comprising therapeutically effective amounts of at least one N-propanoyl derivative of amino acids, aminocarbohydrates, and derivatives thereof. The compositions are useful the prevention and treatment of symptoms or syndromes associated with nervous, vascular, musculoskeletal, or cutaneous systems. The compositions may be topically or systemically administered... Agent: Goodwin Procter LLP

20090186854 - S-alkylisothiouronium derivatives for the treatment of inflammatory diseases: The present invention relates to uses of S-alkylisothiouronium derivatives for treating inflammation. In particular, the present invention provides extended release pharmaceutical dosage forms of S-alkylisothiouronium derivatives and methods of use thereof for the treatment of various inflammatory diseases or conditions.... Agent: Winston & Strawn LLP Patent Department

20090186855 - Compounds and methods for treating toll-like receptor 2-related diseases and conditions: The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation.... Agent: Clark & Elbing LLP

20090186856 - Micronutrient phosphates as dietary and health supplements: There is provided a dietary or health supplement comprising an effective amount of a micronutrient selected from the group consisting of phosphate derivatives of tocopherol, ubiquinol, ascorbic acid, tocotrienol, retinol and mixtures thereof delivered with an acceptable carrier.... Agent: Michael Best & Friedrich LLP

20090186857 - Combretastatin a-4 phosphate prodrug mono- and di- organic amine salts, mono- and di- amino acid salts, and mono- and di- amino acid ester salts: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.... Agent: Oxigene, Inc. C/o Law Offices Of Karen E. Flick

20090186858 - Synergistic compositions: A synergistic composition comprising a THP salt and a biopenetrant, in which the biopenetrant comprises a polymer of an unsaturated carboxylic acid or a copolymer of an unsaturated carboxylic acid with a sulphonic acid, said polymer or copolymer being terminated by a mono- or diphosphonated unsaturated carboxylic acid group or... Agent: Buchanan, Ingersoll & Rooney PC

20090186859 - Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods: Disclosed are compounds that release nitric oxide, e.g., a compound of Formula (I) wherein R1-10, X, and n are as described herein, which are NSAID derivatives comprising a diazeniumdiolate moiety N2O2−. The compounds are chemopreventive agents with gastric-sparing, analgesic, cardioprotective, and/or anti-inflammatory properties. Also disclosed is a pharmaceutical composition comprising... Agent: Leydig, Voit & Mayer, Ltd.

20090186860 - Microbicidal compositions and their use: A composition comprising a copper salt of N′-hydroxy-N-cyclohexyldiazenium oxide (CuHDO) and a diluent is useful for combating and/or killing bacteria, mould, yeast and algae in industrial materials and or industrial processes. In a preferred embodiment CuHDO is generated in-situ within the application or medium. The composition may additionally include at... Agent: Connolly Bove Lodge & Hutz, LLP

20090186861 - Process for production of fatty acids, fatty acid esters and sterolesters from soapstock: c

20090186862 - Treatment of cystic fibrosis: The present invention discloses a therapeutic target for the treatment of cystic fibrosis. It was found that inhibition of non-lysosomal glucosylceramidase (GBA2) sufficiently restores chloride current in cells from CF patients carrying the common delF508-CFTR mutation. With the catalytic centre (4) of the enzyme positioned on top of the membrane... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090186863 - Use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug: The present invention relates to the use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug, with the exception of a neuroprotective drug.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090186864 - Ruthenium (ii) compounds: or RN1 and RN2 together with the pyridine rings to which they are bound form an tricyclic heteraromatic moiety, where the ring formed by RN1 and RN2 together may be optionally substituted by one or more substituents represented by RC3 selected from: hydroxy, C1-7 alkoxy, C5-20 aryloxy, C1-7 alkyl, carboxy,... Agent: Curatolo Sidoti Co., Lpa

20090186865 - Lyophilization process: An improved process for the production of lyophilized Piperacillin alone or in combination with Tazobactam with improved pH adjustment, by degassing the solution of products to a controlled low carbon dioxide content prior to lyophilization.... Agent: Sandoz Inc

20090186866 - Therapeutic beta-lactams:

20090186867 - Substituted diketopiperazines as oxytocin antagonists: A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090186868 - Taxane compound having azetidine ring structure: A compound represented by the general formula (1) [X1 and X2 represent hydrogen atom, a halogen atom, hydroxyl group and the like, R1 represents a phenyl group, R2 represents an alkyl group, an alkenyl group, or an alkoxy group, R3 represents hydrogen atom, a halogen atom, hydroxyl group, or an... Agent: Greenblum & Bernstein, P.L.C

20090186869 - Antiviral compounds: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20090186870 - Therapeutic agents - 802: e

20090186871 - Tyrosine kinase inhibitors: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable... Agent: Merck And Co., Inc

20090186872 - Loxapine analogs and methods of use thereof: The invention relates to novel compounds and methods of using them for modulating sleep.... Agent: Eli Lilly & Company

20090186873 - Kappa selective opioid receptor antagonist: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.... Agent: Eli Lilly & Company

20090186874 - Carboxamide derivative and use thereof: wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B and ring C are each an aromatic ring optionally having substituent(s), R1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group or a heterocyclic group optionally having substituent(s), Z is an optionally halogenated... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090186875 - Compounds for the treatment of inflammatory diseases: and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090186876 - Pyridine analogues ii: The present invention relates to certain new pyridin analogues of Formula (I) [Chemical formula should be inserted here. Please see paper copy] Formula (I) to processes for preparing such compounds, to their utility in medicine in general and especially as P2Y12 inhibitors and as anti-trombotic agents etc, their use as... Agent: Pepper Hamilton LLP

20090186877 - Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors: e

20090186878 - Crystalline forms of a farnesyl dibenzodiazepinone: The present invention relates to crystalline forms of ECO-4601 and the processes for providing them. The invention further relates to pharmaceutical compositions comprising the crystalline forms and to methods of use of the crystalline forms as pharmaceuticals.... Agent: Merchant & Gould PC

20090186879 - Tricyclic compounds and use thereof: wherein x is a nitrogen or CRx, Rx is a hydrogen, etc., R1 is an optionally substituted hydrocarbon group, etc., R2 is an optionally substituted hydrocarbon group, etc., ring A is 5- to 8-membered heterocyclic ring, etc., and each of Y1, Y2 and Y3 is an optionally substituted carbon or... Agent: Edwards Angell Palmer & Dodge LLP

20090186881 - Cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: wherein R1, R2, R3, R4 and X are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090186880 - Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as... Agent: Birch Stewart Kolasch & Birch

20090186882 - Cgrp receptor antagonists: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.... Agent: Vertex Pharmaceuticals Inc.

20090186883 - Stable aqueous suspension: An aqueous pharmaceutical suspension comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) an aqueous buffer system; (iii) xanthan gum; (iv) polyvinyl pyrrolidone; and (v) glycerol wherein the suspension is free from pregelatinised starch, amino polycarboxylic acid, microcrystalline cellulose, hydroxypropylmethyl cellulose, polyoxyethylene sorbitan monooleate, silicon dioxide and taste modifying agents... Agent: Whyte Hirschboeck Dudek S C Intellectual Property Department

20090186884 - Diaminopropanol renin inhibitors: Described are diaminopropanols of which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of renin activity or in the treatment of aspartic protease mediated disorders. Also described is a method for the use... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090186885 - Therapeutic compounds: s

20090186888 - Novel fused pyrrolocarbazoles: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.... Agent: Ross J. Oehler Cephalon, Inc.

20090186887 - Novel pyrimidothienoindazoles: e

20090186886 - Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments:

20090186889 - Spiro-substituted pyrrolopyrimidines: wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid... Agent: Novartis Institutes For Biomedical Research, Inc.

20090186892 - Methods for treating lung cancers: The present invention provided methods for treating lung cancers using therapeutic agents for lung cancers comprising erbB receptor inhibitors as active ingredients. Methods for examining the responsiveness of lung cancer patients to erbB receptor inhibitors by using blood amphiregulin (AREG) as an indicator were provided. Furthermore, methods for treating lung... Agent: Townsend And Townsend And Crew, LLP

20090186891 - Organic compounds: e

20090186890 - Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative: A pharmaceutical composition comprising 4-(3′-chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The water-soluble cellulose ether or ester of a water-soluble cellulose ether present in the composition inhibits the rate of precipitation of the Agent from... Agent: Morgan Lewis & Bockius LLP

20090186893 - Ire-1alpha inhibitors: Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.... Agent: Banner & Witcoff, Ltd.

20090186894 - N-substituted-heterocycloalkyloxybenzamide compounds and methods of use: m

20090186895 - Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial... Agent: Fish & Richardson P.C.

20090186898 - Inhibitors of bruton's tyrosine kinase: wherein R, R′, R″, Q, X, and Y are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with... Agent: Grant D. Green Patent Law Department

20090186896 - Pde inhibitors and combinations thereof for the treatment of urological disorders: The invention provides pharmacological compositions comprising PDE-5 and PDE-4 inhibitors, alone or in combination, for the treatment of urological disorders comprising Benign Prostate Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS) and in particular irritative symptoms caused by BPH-induced bladder outlet obstruction (BOO). The invention also provides methods of screening for... Agent: Barbara A. Shimei Director, Patents & Licensing

20090186897 - Phthalazinone derivatives: wherein RH represents one or more optional substituents on the fused cyclohexene ring; R1 is selected from H and halo; RN is selected from H and optionally substituted C1-10 alkyl; and RC1 and RC2 are independently selected from H, R, C(═O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted... Agent: Morgan Lewis & Bockius LLP

20090186899 - Substituted sulfonamide compounds: wherein m, n, p, Q, R1, R2, R3, R4, X, Y and Z have the respective meanings defined herein, pharmaceutical compositions containing such compounds, a process for their preparation, and the use of such compounds for the treatment and/or inhibition of pain and other conditions mediated by bradykinin receptor 1... Agent: Crowell & Moring LLP Intellectual Property Group

20090186900 - Compound: e

20090186901 - Chemical compounds: The present invention relates to new heterocyclic compounds of general formula (1) wherein the groups R1 to R7, k, X and Y have the meanings given in the claims and specification, the isomers and salts thereof as well as the use thereof as medicaments. Background to the invention WO 01/36423... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090186902 - Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions: e

20090186903 - Aripiprazole complex formulation and method: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or... Agent: Louis J. Wille Bristol-myers Squibb Company

20090186904 - Substituted oxindole derivatives, medicaments containing the latter and use thereof: The invention relates to novel oxindole derivatives of general formula (I), in which the substituents A, B, R1, R2 and R3 are defined as cited in claim 1, to medicaments containing said derivatives and to the use of the latter for the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.... Agent: Dykema Gossett PLLC

20090186905 - Anaplastic lymphoma kinase modulators and methods of use: The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R1, R2, R3 and R4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. The invention provides compounds for modulating protein kinase enzymatic activity... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090186906 - Furo[3, 2-b] pyrrol derivatives: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: R3 is ten-butylmethyl, sec-butyl or tert-butyl; X is CH or N; and R4 is optionally substituted C1-8 alkyl or optionally substituted C3-8 cycloalkyl. The invention further relates to pharmaceutical compositions comprising compounds of formula (I),... Agent: Edwards Angell Palmer & Dodge LLP

20090186907 - Pyrazinones as cellular proliferation inhibitors: e

20090186909 - Oxadiazolidinedione compound: [Means for resolution] It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090186908 - Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy: The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such... Agent: Morgan Lewis & Bockius LLP

20090186910 - Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors: Methods are disclosed for determining whether organ toxicity, particularly cardiotoxicity, will occur in a patient selected for treatment with various kinase inhibitors, such as tyrosine kinase inhibitors, more particularly erbB inhibitors such as Herceptin. In addition, methods are disclosed for determining whether a potential drug is likely to produce a... Agent: K&l Gates LLP

20090186911 - Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments: The present invention relates to sulphoximine-substituted quinazoline derivatives of the formula (I), processes for their preparation and their use as a medicament for the treatment of various diseases.... Agent: Millen, White, Zelano & Branigan, P.C.

20090186912 - Anti-infective agents and uses thereof: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts,... Agent: Paul D. Yasger Abbott Laboratories

20090186913 - Tetrahalogenated compounds useful as inhibitors of angiogenesis: Methods for inhibiting a neoplasm in a subject and methods of inhibiting undesired angiogenesis that include administering to a subject a therapeutically effective amount of at least one novel tetrahalogenated compound, or a pharmaceutically acceptable salt thereof.... Agent: Klarquist Sparkman, LLP

20090186914 - Phenylalanine enamide derivatives: The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090186915 - Compositions and methods for treatment of glioblastoma, gliosarcoma, nsclc, and head and neck cancer: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast... Agent: Davidson, Davidson & Kappel, LLC

20090186916 - Aminoindane derivative or salt thereof: A novel compound or a salt thereof, which is characterized in that it has an amino group and R1 (lower alkyl, cycloalkyl, -lower alkylene-aryl, aryl which may be substituted, and the like) on carbon atoms of indane, cyclopenta[b]thiophene, cyclopenta[b]furan, cyclopenta[b]pyridine, or cyclopenta[c]pyridine ring, or 2,3-dihydrdo-1-benzofuran, 2,3-dihydrdo-1-benzothiophene, indoline ring, or the... Agent: Fitzpatrick Cella Harper & Scinto

20090186917 - 6-and 7-amino isoquinoline compounds and methods for making and using the same: 6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6- and 7-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such... Agent: Michael Best & Friedrich LLP

20090186918 - Triazole compounds as lipoxygenase inhibitors: There is provided compounds of formula (I) wherein W is an optionally substituted aryl or heteroaryl group, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment... Agent: Morgan Lewis & Bockius LLP

20090186919 - Piperidine derivatives for treatment of alzheimer's disease: Compounds of formula (I) modulate the activity of gamma secretase and hence find use in treatment or prevention of Alzheimer's disease and related conditions.... Agent: Merck And Co., Inc

20090186920 - Sulfonamides as orexin antagonists: m

20090186921 - Azacyclic compounds: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.... Agent: Knobbe Martens Olson & Bear LLP

20090186922 - 2-arylindole derivatives as npges-i inhibitors: A 2-arylindole compound substituted in position 5, of formula (I): in which X, Y, Z, W, A, R and R′ have the meanings given in the description, a pharmaceutical composition comprising it, and also intermediate compounds and a preparation process therefor.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090186923 - Compounds having crth2 antagonist activity: 2

20090186924 - Substituted arylpyrazoles: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20090186925 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent: Dykema Gossett PLLC

20090186926 - Self-emulsifying formulations of cetp inhibitors: A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.... Agent: Merck And Co., Inc

20090186927 - Trans-9,10-dehydroepothilone c and d, analogs thereof and methods of making the same: The present invention provides new trans-9,10-dehydroepothilone C and trans-9,10-dehydroepothilone D based derivative compounds, compositions and methods of inhibiting cellular hyperproliferation and/or stabilizing microtubules in vitro and of treatment of hyperproliferative diseases in vivo. Also disclosed are methods of making the compounds.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090186928 - Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1: Novel crystalline salts of 3-[1-(4-chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-1,2,4-triazole are potent inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions... Agent: Merck And Co., Inc

20090186929 - Method and agent for inducing apoptosis/cell death in leukemia cells: A method for inducing apoptosis or cell death in leukemia cells includes inhibiting the production of nitric oxide (NO) by using a nitric oxide synthase (NOS) inhibitor. The NOS inhibitor includes a NOS1-specific inhibitor, such as N-[4-(2-{[(3-chlorophenyl)methyl]amino}ethyl)phenyl]-2-thiophenecarboximide dihydrochloride, [N5-(1-imino-3-butenyl)-L-ornithine], 7-nitroindazole, 1-(2-trifluoromethylphenyl)imidazole, 3-bromo-7-nitroindazole, and S-ethyl-N-[4-(trifluoromethyl)phenyl)isothiourea HCl.... Agent: Dinesh Agarwal, P.C.

20090186930 - Novel imidazole derivatives, preparation and user thereof as medicine: The invention concerns novel imidazole derivatives of general formula (I), wherein Z′ and Z represent different variable groups. Said products have an antitumoral activity. The invention also concerns pharmaceutical compositions containing said products and their use for preparing antitumoral medicine.... Agent: Hunton & Williams LLP Intellectual Property Department

20090186931 - Dinitropyrazole derivatives, their preparation, and energetic compositions comprising them: e

20090186932 - Pesticidal n-phenylpyrazole derivatives: The invention relates to 5-(substituted dithio- or dioxy-alkylamino)pyrazole derivatives of formula (I) or salts thereof: wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Frommer Lawrence & Haug

20090186933 - Indole, azaindole and related heterocyclic pyrrolidine derivatives: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with amido piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the... Agent: Louis J. Wille Bristol-myers Squibb Company

20090186934 - Beta crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it.: i

20090186935 - Taste titration therapies: The teachings provided herein generally relate to formulations, systems, and methods that have the ability to remit deficiencies and imbalances in a subject's serotonin and dopamine levels. The teachings relate to the preparation and uses of a formulation comprising a serotonergic agent or dopaminergic agent in a form capable of... Agent: Tips Group C/o Intellevate LLC

20090186937 - Method for treating addiction using quercetin-containing compositions: This invention relates to a method of treating addiction using a composition containing quercetin. Preferably, it also contains vitamin B3, and vitamin C.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090186936 - Tea beverages containing proanthocyanidins: The object is attained by providing proanthocyanidins containing tea beverages that contain procyanidin B1 (PB1) and procyanidin B3 (PB3) in a total amount not smaller than a certain concentration and which are free from any peculiar flavor to become easier to drink; they allow for sustained intake and have an... Agent: Drinker Biddle & Reath (dc)

20090186938 - Antitumoral dihydropyran-2-one compounds: Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus Lithoplocamia, species lithistoides, and derivatives thereof are provided.... Agent: King & Spalding

20090186939 - Method of treating chronic kidney disease: The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090186940 - Synthesis of scabronines and analogues thereof: A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as... Agent: Choate, Hall & Stewart LLP Sloan-kettering Institute For Cancer Research

20090186941 - Organic sulfur compounds and use thereof: n

20090186942 - Novel nutraceutical and pharmaceutical compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders: The invention relates to novel compositions comprising a phenolic compound as well as to the use of these compositions as a medicament, in particular for the manufacture of a nutraceutical or pharmaceutical composition for the treatment, co-treatment or prevention of inflammatory disorders, such as arthritis, asthma, inflammatory bowel diseases, inflammatory... Agent: Nixon & Vanderhye, PC

20090186943 - Antiseptic ointment: Disclosed is a microbicidal and antiseptic ointment which contains at least one kind selected from the group consisting of chlorhexidine and its salt in an amount from 0.1 to 4 mass % and a hydrocarbon alcohol having 2 to 3 carbon atoms in an amount from 8 to 25 mass... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090186944 - Prevention and treatment of breast cancer with 4-hydroxy tamoxifen: Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients... Agent: Foley And Lardner LLP Suite 500

20090186945 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090186946 - Genetically modified animal and use thereof: The present invention provides a non-human mammal deficient in the expression of the SLC-1 gene, having the characteristics of (1) a lower blood insulin level in glucose tolerance test, (2) increased insulin sensitivity, (3) higher resistance to obesity even on high fat diet, (4) a smaller white fat cell size,... Agent: Edwards Angell Palmer & Dodge LLP

20090186947 - Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride: A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.... Agent: Crowell & Moring LLP Intellectual Property Group

20090186948 - Use of combinations of methyl ethyl ketone peroxide by spraying: Composition of Methyl Ethyl Ketone Peroxide as biocide, applied by spraying, for human and veterinary hygiene; of utility in the private sphere and in public health and, particularly, conserving the organic matter of its natural surface decomposition due to the passage of time until the collection for treatment and/or elimination,... Agent: Sughrue Mion, PLLC

20090186949 - Method for treating endothelial and epithelial cell disorders by administering high molecular weight peg-like compounds: The invention provides methods of screening for modulators of microbial PA-I lectin/adhesin activity, including modulators of PA-I expression, as well as the modulators so identified, pharmaceutical compositions and kits containing such modulators. These modulators include soluble and membrane-bound bacterial signaling compounds produced by cells of a host containing a microbial... Agent: Marshall, Gerstein & Borun LLP

20090186950 - 13,13-dimethyl-des-c,d analogs of 1alpha,25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof: 13,13-Dimethyl-des-C,D analogs of 1α,25-dihydroxy-19-nor-vitamin D3 compounds and topical composition dosage forms thereof, and methods of treating skin conditions thereof. Exemplary active pharmaceutical ingredients include (1R,3R)-5-[(E)-(S)-11′-hydroxy-5′,5′,7′,11′-tetramethyl-dodec-2′-enylidene]-2-metylene-cyclohexane-1,3-diol, (1R,3R)-5-[(Z)-(S)-11′-hydroxy-5′,5′,7′,11′-tetramethyl-dodec-2′-enylidene]-2-metylene-cyclohexane-1,3-diol, (1R,3R)-5-[(E)-(R)-11′-hydroxy-5′,5′,7′,11′-tetramethyl-dodec-2′-enylidene]-2-metylene-cyclohexane-1,3-diol, and (1R,3R)-5-[(Z)-(R)-11′-hydroxy-5′,5′,7′,11′-tetramethyl-dodec-2′-enylidene]-2-metylene-cyclohexane-1,3-diol.... Agent: Quarles & Brady LLP

20090186951 - Identification of novel pathways for drug development for lung disease: The invention provides the identification of oncogenic pathways activated in cytologically normal airway cells of individuals having or at risk of having lung disease, as well as specific gene expression patterns (biomarkers) associated with pathway activation. These biomarkers and pathways may provide prognostic and/or diagnostic indicators in lung disease, e.g.,... Agent: Morse, Barnes-brown & Pendleton, P.C. Attn:IPManager

  
07/16/2009 > patent applications in patent subcategories. category listing

20090181879 - Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase a2: The present invention relates to methods useful to monitor central and peripheral nervous system neuron/axon destruction resulting from an increase in acute phase inflammatory enzymes. The methods have applicability to monitoring the progress of neurological diseases, including multiple sclerosis and Alzheimer's disease, as well as neuroinflammatory damage that results from... Agent: Drinker, Biddle & Reath

20090181880 - Methods for treatment of headaches by administration of oxytocin: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.... Agent: Morrison & Foerster LLP

20090181881 - Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders: The invention provides a method for reducing or inhibiting net beta-amyloid peptide production and amyloid plaque formation associated with Alzheimer's Disease by administering to a subject an amount of a netrin-1 polypeptide, wherein the netrin-1 polypeptide comprises an amino acid sequence that a) binds to a naturally occurring APP protein... Agent: Goodwin Procter LLP Patent Administrator

20090181883 - Human chorionic gonadotropin (hcg) formulations for facilitating weight loss and body contouring: The present invention relates to formulations of hCG for sublingual administration to mammals to facilitate weight loss and/or body contouring. Embodiments of the invention disclose administration of hCG formulations in combination with a low calorie diet and dietary supplements and, in some cases, with an exercise regime. Embodiments of this... Agent: Knobbe Martens Olson & Bear LLP

20090181882 - Methods and preparations for curing critically ill patients: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090181890 - Amylin and amylin agonists for treating psychiatric diseases and disorders: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090181894 - Chimeric toxins for targeted therapy: The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting moieties consist of gonadotropin releasing hormone homologues and the cell killing moieties consist of Pseudomonas Exotoxin A. The... Agent: Volpe And Koenig, P.C.

20090181889 - Compositions and methods for detection and treatment of human herpesvirus (hhv)-6: Disclosed herein are compositions and methods for detection and treatment of human herpesvirus (HHV)-6.... Agent: Fish & Richardson P.C.

20090181886 - Method for determining the concentration of the adipocytic form of the fatty acid binding protein (a-fabp, fabp4, p2): The invention relates to products and methods for the research, diagnosis, risk assessment, course monitoring, treatment and prophylaxis of various metabolic disorders and their early forms, concomitant diseases and secondary diseases. Metabolic diseases in the aforementioned sense include, among others, metabolic syndrome, non-insulin-dependent diabetes, (type II diabetes), insulin resistance, obesity... Agent: Buchanan Ingersoll & Rooney PC

20090181892 - Methods and kits for treating joints and soft tissues: Methods to treat and provide pain relief for damaged and degenerated tissues of a musculoskeletal joint are disclosed. These methods include introducing into, around and/or on the musculoskeletal joint an effective amount of biocompatible matrix or biocompatible polymeric compound to reduce pain associated with the damaged and degenerated tissues of... Agent: Andrews Kurth LLP

20090181884 - Novel apolipoprotein gene involved in lipid metabolism: Methods and materials for studying the effects of a newly identified human gene, APOAV, and the corresponding mouse gene apoAV. The sequences of the genes are given, and transgenic animals which either contain the gene or have the endogenous gene knocked out are described. In addition, single nucleotide polymorphisms (SNPs)... Agent: Townsend And Townsend And Crew, LLP

20090181885 - Novel compounds and their effects on feeding behaviour: t

20090181891 - Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer: A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene... Agent: Agensys C/o Morrison & Foerster LLP

20090181888 - Skin repair accelerating therapeutic agent containing ghrelin and derivatives thereof or substance acting on ghs-r1a as active ingredient: The present invention provides a novel therapeutic agent for skin injuries and a skin regeneration accelerator. The therapeutic agent for skin injuries and the skin regeneration accelerator containing a substance acting on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090181895 - Stabilised compositions of factor vii polypeptides: The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090181887 - Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort: The present invention relates to molecules, compositions and methods suitable for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree. The peptide hormone glucagon-like peptide-1 (GLP-1) has both anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract. GLP-1 exists in several... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090181893 - Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balanc: The present invention provides compositions and methods for treating otic disorders. More specifically, the present invention describes the use of agents that down-regulate expression of Tanis and/or p21Waf1/Cip1/Sd1 genes to treat such disorders of the ear.... Agent: Alcon

20090181896 - Use of natriuretic peptide receptor antagonists to treat ocular, otic and nasal edemetous conditions: Methods and compositions to treat edematous ocular, otic and nasal conditions are described.... Agent: Alcon

20090181897 - Cxcr4 antagonist and use thereof: The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090181898 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090181899 - Low-molecular weight peptides inhibiting ion channel activity: It is intended to provide novel polypeptides which specifically inhibit the activity of a mechano-sensitive channel; and mechano-sensitive channel inhibitors or remedies for atrial fibrillation containing these polypeptides or salts thereof. The above objects can be achieved by using polypeptides having amino acid sequences represented by SEQ ID NO: 1... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090181900 - Novel peptides and methods for the treatment of inflammatory disease: The invention relates to an isolated peptides comprising at least the amino acid sequence YDRREY or a derivative thereof, nucleic acids encoding the peptides, pharmaceutical compositions and methods for modulating β7 integrin function, including methods for treatment of inflammatory disorders, antibodies directed to said peptides and methods for identification of... Agent: Occhiuti Rohlicek & Tsao, LLP

20090181901 - Compositions and methods to increase bioavailability of carotenoids: The present invention relates to compositions and methods of use to increase the bioavailability of a carotenoid in a subject. The compositions include a carotenoid and either an anthocyanin or a compound having at least one —SH group or combinations of both an anthocyanin and a compound having at least... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20090181902 - Modulators of pharmacokinetic properties of therapeutics: e

20090181903 - Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly: Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly by delivering a selection of amino acids, carnitine, and carboydrates with a low glycemic index.... Agent: Lewis, Rice & Fingersh, Lc Attn: BoxIPDept.

20090181904 - Method for regulating nutrient absorption with ginsenosides: The present application relates to a method of regulating nutrient absorption in a subject in need thereof with an isolated ginsenoside compound.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090181905 - Crystalline form of 1' -(1-methylethyl)-4' -[(2-fluoro-4-methoxyphenyl)methyl]-5' -methyl-1h-pyrazol-3' -o-beta-d-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments: The invention relates to a crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090181906 - Combination therapies using melengestrol acetate and zilpaterol or its salts: This invention generally relates to a method for promoting growth and increasing feed utilization efficiency in animals, and, more specifically, to combinations comprising zilpaterol (and salts thereof) and melengestrol acetate. Included within this invention are treatment methods comprising the administration of such combinations to animals, compositions comprising such combinations, uses... Agent: Intervet/schering-plough Animal Health Patent Department

20090181907 - Drug comprising as the active ingredient proliferative vector containing survivin promoter: It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of... Agent: Occhiuti Rohlicek & Tsao, LLP

20090181912 - Glp/1/exendin 4 igg fc fusion constructs for treatment of diabetes: The invention is a method and composition for the prevention and treatment of type I and type II diabetes in a subject. The composition comprises an IgG-Fc fusion protein where the fusion protein comprises GLP-1, mutant GLP-1, or exendin-4.... Agent: Bereskin And Parr

20090181918 - Inhibition of pathological angiogenesis in vivo: The present invention is directed to the inhibition of pathological angiogenesis in different tissues such as cancer, tumor, retinal or synovial tissue. It has been shown that over expression of RB2/p130 modulates the angiogenetic balance. It has been further shown that induction of RB2/p130 expression using a tetracycline-regulated gene expression... Agent: Reed Smith LLP

20090181916 - Lna antagonists targeting the androgen receptor: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of androgen receptor expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and... Agent: Dechert LLP

20090181914 - Lna oligonucleotides and the treatment of cancer: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx)(Gx)(c)-3′, and preferably of the general formula 5′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′, wherein capital letters designate an LNA nucleotide analogue selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as... Agent: Dechert LLP

20090181917 - Men1 gene for diagnosis and treatment of diabetes: This invention relates to the inhibition of expression or function of Men1 gene or its encoded proteins for the purpose of treating diabetes and screening and researching agents capable of inhibiting expression or function of Men1 gene or its encoded proteins for use in the treatment and diagnosis of diabetes.... Agent: Pearl Cohen Zedek Latzer, LLP

20090181919 - Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes: This invention relates generally to the freeze-drying of formulations comprising a polynucleotide, a block copolymer and a cationic surfactant. In the presence of a cryoprotectant or bulking agent, a formulation can be freeze-dried, whereby upon reconstitution of the dried formulation, the microparticles maintain their optimal size and aggregation or fusion... Agent: Karen B. Dow Dla Piper LLP (us)

20090181910 - Method of prevention and alleviation of toxicity by modulation of irf3: The invention provides compounds, compositions, animal models, drug screening methods, pharmaceutical compositions, and methods of treatment which relate to the modulation of the metabolism of xenobiotic compounds by administering agents which act on IRF3 or an IRF3 control pathway to modulate the activity, expression, or levels of cytochrome P450 enzymes... Agent: Townsend And Townsend And Crew, LLP

20090181908 - Methods and compositions for treating keratin hyperproliferative disorders: A method for keratin hyperproliferation disorders such as corns, calluses, or keratosis pilaris (KP) by administering to a subject experiencing the disorder a therapeutically effective amount of an RNA sequence which inhibits expression of a gene encoding for a keratin selected from the group consisting of K6a, K6b, K16, K17,... Agent: Thorpe North & Western, LLP.

20090181911 - Role of gax in alzheimer neurovascular dysfunction: Neurovascular disorder critically contributes to the development and pathogenesis of Alzheimer's disease (AD). Transcriptional profiling of human brain endothelial cells (BEC) defines a subset of age-independent genes significantly altered in AD including the homebox gene GAX whose expression controls vascular phenotype and is low in AD. By using viral-mediated GAX... Agent: Nixon & Vanderhye, PC

20090181913 - Specific grp78 expression-inhibition rnai sequence, medicine thereof and method thereof: The present invention discloses a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof and a method thereof, wherein an RNAi sequence 5′-AAGGATGGTTAATGATGCTGAGAA-3′ complementary to GRP78 forms a special hair-pin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration,... Agent: Sinorica, LLC

20090181915 - Transcription factor arntl2 gene and expression products thereof used in the diagnosis, prevention, and treatment of type 1 diabetes: The present application identifies the involvement of the HIFβ-homologous Arntl2 gene in the control of type 1 (insulin-dependent) diabetes. Accordingly, the present invention provides a method of determining the susceptibility of a subject to developing insulin-dependent diabetes based on the expressing level of the Arntl2 gene. The present invention also... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090181909 - Vasopressin-binding l-nucleic acid: The invention relates to a vasopressin-binding nucleic acid, characterized in that the nucleic acid has a Box 1 segment The and a Box 2 segment, Box 1 having the sequence GAGS, in which W=A or U, preferably W=U, and Box 2 having a sequence comprised of approximately 18 to 24... Agent: Mdip LLC

20090181920 - Intrathecal treatment of neuropathic pain with a2ar agonists: The present invention relates to a method of treating neuropathic pain via intrathecal administration of agonists of A2A adenosine receptors (ARs).... Agent: Clinical Data, Inc.

20090181921 - 2-5a analogs and their methods of use: Disclosed herein are compounds that activate RNaseL, methods of synthesizing compounds that activate RNaseL and the use of compounds that activate RNaseL for treating and/or ameliorating a disease or a condition, such as a viral infection, cancer and/or parasitic disease.... Agent: Knobbe Martens Olson & Bear LLP

20090181922 - Palatinose for enhancing dietary supplement and pharmaceutical delivery: The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of... Agent: Morse, Barnes-brown & Pendleton, P.C. Attn:IPManager

20090181924 - Compositions comprising glycosaminoglycans of low viscosity and use of said composition in therapy of chronic cystitis: The present invention concerns new compositions comprising glycosaminoglycans, intended for use in interstitial cystitis therapy, and characterized by a controlled viscosity.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090181925 - Compositions for treating and preventing hyperlipidemia: A composition for treatment and prevention of hyperlipidemia consists of phytosterols and phytostanols 30-50%, flavones derived from bamboo leaf 20-40%, procyanidins 10-25% and β-glucan of 5-20% by weight. Said composition demonstrates markedly therapeutic effects on preventing and treating hyperlipidemia, compared with the combinations of two or three components selected from... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090181923 - Method of increasing weight gain and reducing diarrhea morbidity, mortality and severity by stimulation of natural immune response, nutritional support of immune function and supplemental nutricines and probiotics: A method for the promotion of growth and weight gain, the abatement of diarrheal disease and the reduction in mortality in a farm animal comprising administering bacterial polysaccharides derived from dried rumen fluid combined with nutritional aids is described. The use of a specialized nutritional composition the first few days... Agent: Robert T. Winn Dvm

20090181926 - Skin external preparation having excellent stability: Disclosed is an agent for skin external preparation which is hardly reduced in viscosity even when stored for a long period under extreme high temperature storage conditions and is therefore stable. The preparation is in an emulsion form, and comprises (1) an alginic acid polyol ester having an esterification degree... Agent: Knobbe Martens Olson & Bear LLP

20090181927 - Bonding tissues and cross-linking proteins with naphthalimide compounds: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such... Agent: T. Ling Chwang Jackson Walker L.L.P.

20090181928 - Organic compounds: are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds... Agent: Novartis Institutes For Biomedical Research, Inc.

20090181929 - Organic compounds: e

20090181930 - Kinase inhibitory phosphonate analogs: The invention is related to phosphorus substituted kinase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20090181931 - Antiviral activity of cidofovir against oncolytic viruses: The present invention relates to pyrimidine compounds and their use as pharmacologically active agents capable of suppressing and inhibiting viruses (e.g., oncolytic viruses). The subject compounds and compositions are particularly useful in treating and suppressing human oncolytic adenovirus infection.... Agent: Darby & Darby P.C.

20090181932 - Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as beta-amyloid inhibitors: wherein R1 is substituted aryl or substituted heteroaryl; R2 and R3 are independently selected from the group consisting of CF3, substituted phenyl, C1-C4 alkyl, substituted C1-C4 alkyl, (CF3)nC1-C4alkyl, (CF3)n(substituted C1-C4 alkyl), provided that when R2 or R3 is CF3, the other is not an unsubstituted alkyl; R4 and R4′ are... Agent: Howson & Howson LLP / Wyeth

20090181933 - Use of steroids to treat persons suffering from ocular disorders: Methods and compositions for treating retinal edema and NPDR are disclosed.... Agent: Teresa J. Schultz R&d Counsel (q-148)

20090181935 - Compositions comprising an antimuscarinic and a long-acting beta-agonist: Compositions which comprise a combination of a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo [2.2.2]octane, and a long-acting phenylalkylamino beta2-agonist are effective for the prevention and treatment of inflammatory or obstructive airways diseases.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090181934 - Organic compounds: A composition comprising, separately or together: a component (A) that is an adenosine A2a receptor agonist as defined in the specification; and a component (B) that is one or more compounds selected from: (i) a corticosteroid, (ii) a beta-2 adrenoceptor agonist, (iii) an antimuscarinic agent, (iv) an A2B antagonist, (v)... Agent: Novartis Institutes For Biomedical Research, Inc.

20090181936 - Diene and triene compounds and formulations: The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it... Agent: Hollis-eden Pharmaceuticals, Inc.

20090181937 - Cross-linked fatty acid-based biomaterials: Fatty acid-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090181939 - Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders: Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors, such as obesity, wherein: R1 is aryl or heteroaryl; R2 is alkyl, aryl or heteroaryl; R3 is alkyl, aryl, heteroaryl, NR9R10, OR15, or NR16C(O)R17; Y is C═O, C═S, SO2, or... Agent: Banner & Witcoff, Ltd.

20090181938 - Aminopyrimidines useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.... Agent: Vertex Pharmaceuticals Inc.

20090181940 - Imidazopyrazine tyrosine kinase inhibitors: e

20090181941 - Pyrrolopyrimidines and pyrrolopyridines:

20090181942 - Tricyclic compounds: Since the compounds according to the present invention exhibit an excellent squalene synthetase inhibitory effect and cholesterol synthesis inhibitory effect so that they are useful as a drug such as preventive and/or remedy for diseases in mammals including humans such as hyperlipemia, e.g., hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterolemia and/or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090181943 - Inhibitors of histone deacetylase: n

20090181944 - Method for cancer therapy:

20090181945 - Two cyclic cinnamide compound: wherein represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z1 represents a methylene group or vinylene group,... Agent: Birch Stewart Kolasch & Birch

20090181946 - Benzaepinones as sodium channel blockers: Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel... Agent: Merck And Co., Inc

20090181947 - Bicyclic enamino(thio)carbonyl compounds: The present invention relates to novel bicyclic enamino(thio)carbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090181949 - 1h-imidazole derivative having cb1, agonistic, cb1 partial agonistic or cb1 antagnistic activity: The present invention relates to a group of novel 1H-imidazole derivatives, to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component. These 1H-imidazole derivatives are potent cannabinoid-CB1 receptor agonists, partial agonists or antagonists, useful for the treatment... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090181948 - Diamine derivative: e

20090181950 - Histamine receptor antagonists comprising an azepin core: The present invention relates to compounds of formula (I), and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders, such as allergic rhinitis.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090181951 - Parp inhibitors: A compound of the formula (I), and pharmaceutically acceptable salts thereof, wherein: R2, R3, R4 and R5 are independently selected from the group consisting of H, C1-7 alkoxy, amino, halo or hydroxy; Y is —CRC1RC2—(CH2)m—, where m is 0 or 1, Rc1 is selected from CH3 and CF3, and Rc2... Agent: Michael Best & Friedrich LLP

20090181953 - Compound forms and uses thereof: The present invention provides, among other things, forms of a compound of formula 1. In some embodiments, the present invention provides salt forms and/or crystal forms. In some embodiments, the present invention provides solid forms. The present invention also provides methods of making and using provided forms.... Agent: Choate, Hall & Stewart LLP

20090181952 - Compounds useful as alpha7 nicotinic acetylcholine receptor agonists: The present invention provides compounds and compositions, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.... Agent: Choate, Hall & Stewart LLP/wyeth

20090181954 - Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs: The present invention is drawn to transdermal drug formulations, transdermal patches incorporating such formulations, as well as associated methods. The formulations can include about 0.3 wt % to about 5 wt % of a drug, such as alprazolam, about 4 wt % to about 30 wt % water, about 10... Agent: Thorpe North & Western, LLP.

20090181955 - Antibacterial agents: Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090181956 - Hydrazide compound and pesticidal use of the same: p

20090181957 - Benzimidazolone derivatives as cb2 receptor ligands: This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by CB2 receptor binding activity such... Agent: Pfizer Inc.

20090181958 - Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions: The compounds of the above general formula I as well as the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, and their stereoisomers have valuable pharmacological properties, particularly an antithrombotic activity and a... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090181959 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20090181960 - 17betahsd type 5 inhibitor: It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090181961 - Novel medicaments for the treatment of respiratory diseases:

20090181962 - Substituted thiophene compounds: The invention relates to heteroaromatic carboxamides of formula (I), wherein A, R1, R2, and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20090181963 - 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses: e

20090181965 - Modulators for amyloid beta:

20090181964 - Propane-1,3-dione derivative or salt thereof: It is intended to provide a compound useful as a GnRH receptor antagonist. The inventors further investigated propane-1,3-dione derivatives. As a result, they confirmed that a compound having a benzene ring or a thiophene ring substituted with a group represented by —SO2—R3 in a propane-1,3-dione derivative having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene) has an... Agent: Sughrue Mion, PLLC

20090181966 - Pgd2 receptor antagonists for the treatment of inflammatory diseases:

20090181967 - New compounds i:

20090181969 - Hypotensive lipid and timolol compositions and methods of using same: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional... Agent: Allergan, Inc.

20090181968 - Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides: The present invention relates to compounds of formula (I) [Chemical formula should be inserted here. Please see paper copy] as well as pharmaceutically acceptable salts and pharmaceutical compositions including the compounds are prepared or thereof: wherein, A1, A2, R1, R2, R3, R4, and R5 and n are as defined in... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090181970 - Functionalized diarylisoxazoles inhibitors of ciclooxygenase: The present invention refers to isoxazole derivatives, in particular diarylisoxazole derivatives inhibitors of cyclooxygenase (COX), in particular cyclooxygenase-1 (COX-1), to their pharmaceutical compositions, the process for their preparation and their use for the chemoprevention and treatment of inflammatory syndromes and in the prevention and treatment of carcinomas, in particular intestinal,... Agent: Nixon & Vanderhye, PC

20090181971 - Inhibitors of histone deacetylase: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.... Agent: Keown & Zucchero, LLP

20090181972 - Novel inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.... Agent: Stites & Harbison PLLC

20090181973 - Medicinal composition comprising 3-alkoxy-6-allylthiopyridazines for prevention or treatment of cancer of the pancreas: The present invention relates to a medicinal composition for preventing or treating pancreatic cancer, comprising 3-alkoxy-6-allylthiopyridazine or a pharmaceutically acceptable salt thereof as an effective ingredient. An MTT assay, to assess the viability of cells, and flow cytometric analysis, to measure apoptotic cell death, were performed, and the results, which... Agent: Kenneth I. Kohn Kohn & Associates

20090181974 - Composition for slowing down the development of alzheimer's disease: The invention relates to a composition comprising: vegetable oil containing at least one linoleic acid and at least one linolenic acid, vitamin E, and vitamin B9 (or folates), whereby the linoleic acid/linolenic acid weight ratio is between 3 and 5. The inventive composition is intended to slow down the development... Agent: Blakely Sokoloff Taylor & Zafman

20090181975 - Nebivolol in the treatment of sexual dysfunction: The present invention provides methods of treating sexual dysfunction. The methods include administering an effective amount of nebivolol, or a pharmaceutically acceptable salt thereof, alone or in combination with a second active agent e.g. a PDE-5 inhibitor, such as sildenafil citrate. The methods of the present invention are particularly suited... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090181976 - Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome: The present invention refers to the use of compounds binding to the sigma receptor for the treatment of metabolic syndrome.... Agent: Cooper & Dunham LLP

20090181977 - Anhydrous amorphous imatinib mesylate: Described is a highly stable amorphous form of imatinib mesylate having a water content of less than 0.5 percent by weight, based on the total weight of the amorphous imatinib mesylate, (anhydrous amorphous imatinib mesylate), a process for preparation thereof, and pharmaceutical compositions.... Agent: Cantor Colburn, LLP

20090181978 - 5-ht1a receptor subtype agonist: s

20090181979 - Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties: A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R1-R9 and R12-R14 are as defined herein... Agent: Foley & Lardner LLP

20090181980 - Synergistic pharmaceutical composition: A therapeutic agent for administration to a bacterium or to the environment thereof which agent comprises synergistically effective amounts of (i) an RNA polymerase inhibitor and (ii) an ALS enzyme inhibitor.... Agent: Fish & Richardson P.C.

20090181981 - Crystalline (r)-2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide: Crystalline R-2-(4-cyclopropanesulfonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide and methods of its preparation and use are disclosed.... Agent: Eli Lilly & Company

20090181982 - Substituted pyrroline kinase inhibitors: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.... Agent: Philip S. Johnson Johnson & Johnson

20090181984 - Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use: Due to its pharmacological profile the compound of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent: Birch Stewart Kolasch & Birch

20090181983 - Six-membered heterocycles useful as serine protease inhibitors: or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, R3 and R11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa,... Agent: Louis J. Wille Bristol-myers Squibb Company

20090181985 - Imidazo[1,2-b]pyridazine compound: Wherein R1 denotes a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group and the like; R2 denotes a halogen atom, a cyano group, a nitro group, a C1-10 alkyl group, a C2-10 alkenyl group, C2-10 alkynyl group and the like; R3 denotes a C6-14 aromatic hydrocarbon cyclic group... Agent: Birch Stewart Kolasch & Birch

20090181986 - Substituted heterocyclic compounds: e

20090181987 - Inhibitors of brutons tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson Sonsini Goodrich & Rosati

20090181989 - Purine compunds as hsp90 protein inhibitors for the treatment of cancer: wherein ring A is an aryl or heteroaryl ring or ring system; R1 is hydrogen, fluoro, chloro, bromo, or a radical of formula (IA): —X-Alk1-(Z)m-(Alk2)n-Q (IA) wherein X is a bond, —O—, —S— —S(O)—, —SO2—, or —NH—, Z is —O—, —S—, —(C═O)—, —(C═S)—, —S(O)—, —SO2—, —NRA, or, in either orientation... Agent: Banner & Witcoff, Ltd.

20090181988 - Pyrazolo pyrimidine derivatives and methods of use thereof: This invention generally relates to pyrazolo pyrimidine derivatives useful as, inter alia, inhibitors of short chain dehydrogenase/reductase (SDR) family of NAD(P)(H) dependent oxido-reductases. More specifically, the invention relates to pyrazolo pyrimidine derivatives, including derivatives and analogs of SDR inhibitors, pharmaceutical compositions containing derivatives and analogs of SDR inhibitors, methods of... Agent: Townsend And Townsend And Crew, LLP

20090181990 - Stable amorphous form of pemetrexed disodium: The present invention provides an amorphous form of pemetrexed disodium, a process for preparing the amorphous form of pemetrexed disodium, and a pharmaceutical composition that includes the amorphous form of pemetrexed disodium and a pharmaceutically acceptable excipient. The process for preparing the amorphous form of pemetrexed disodium includes dissolving pemetrexed... Agent: Schwegman, Lundberg & Woessner, P.A.

20090181991 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Lck, IR, IGF-1R, JNK1α, Flt3, Fes, EFGR... Agent: Genomics Institute Of The Novartis Research Foundation

20090181992 - (s)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use: Multicyclic compounds and pharmaceutical compositions comprising them are described, along with methods of their use in the treatment of diseases such as age-associated memory impairment, Alzheimer's disease, Attention-Deficit/Hyperactivity Disorder (ADD/ADHD), autism, Down syndrome, Fragile X syndrome, Huntington's disease, Parkinson's disease, and schizophrenia. Compounds include those of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20090181995 - 2-anilino-4-aminoalkyleneaminopyrimidines: The present invention relates to 2-arylamino-4-(aminoalkylene)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090181993 - Hiv inhibiting 5-heterocyclyl pyrimidines: HIV replication inhibitors of formula (I), N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof, wherein -a1=a2-a3=a4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b1=b2-b3=b4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxycarbonyl; R2 is OH; halo; optionally substituted C1-6alkyl, C2-6alkenyl... Agent: Philip S. Johnson Johnson & Johnson

20090181994 - Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1: Triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.... Agent: Merck And Co., Inc

20090181996 - Substituted quinolones iii: The invention relates to substituted quinolones and to methods for their preparation as well as to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.... Agent: Marshall, Gerstein & Borun LLP

20090181997 - Therapeutic cancer treatments: The invention is directed to use of hedgehog inhibitors in conjunction with chemotherapy in treating cancers, and preventing relapses thereby.... Agent: Morrison & Foerster LLP

20090181998 - Opioid receptor subtype-selective agents: Opioid receptor compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a condition mediated by an opioid receptor by administering an effective amount of the opioid receptor compound to a patient in need thereof.... Agent: Fox Rothschild LLP

20090181999 - Use of compositions containing kappa-opioid receptor antagonists for the treatment of dissociative disorders: The invention relates to the use of a composition comprising kappa opioid receptor antagonists for producing a drug for the treatment of dissociative disorders in humans.... Agent: Patent Central LLC Stephan A. Pendorf

20090182000 - Steroidal compounds as steroid sulphatase inhibitors: e

20090182001 - Inhibitors of checkpoint kinases: The instant invention provides for compounds which comprise fused imidazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.... Agent: Merck And Co., Inc

20090182002 - Tyrosine kinase inhibitors: This invention relates to salt forms of the compound N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide, an inhibitor of tyrosine kinases, in particular the receptor tyrosine kinase MET, that are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation. in particular, the invention relates to the... Agent: Merck And Co., Inc

20090182003 - Methods and compositions for treatment cell proliferative disorders: The present invention provides methods for treating and preventing cell proliferative disorders and conditions comprising administering to a subject resveratrol or an analog thereof.... Agent: Harvard University & Medical School C/o Wolf, Greenfield & Sacks, P.C.

20090182004 - Imiquimod formulation: Solutions of members of the imidazoquinoline family of drugs, such as imiquimod or an analog thereof, are made by combining the drug in a solvent system containing one or more non-aqueous solvents and a hydrogen bond forming compound, wherein the solvent system contains a low level of water.... Agent: Howard Eisenberg, Esq.

20090182005 - Prevention and treatment of colorectal carcinomas with imidazoquinoline derivatives: The invention relates to treating of colorectal diseases such as polyps, precancerous stages, and prevention and adjuvant treatment of colorectal cancer by topical administration of immunomodulating drugs of the imidazoquinoline family, such as imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine), resiquimod (4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), sotirimod (2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine).... Agent: Venable LLP

20090182006 - Salt of naphthyridine carboxylic acid derivative: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090182007 - Organic compounds: said compound is inhibitor of aldosterone synthase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosderosis,... Agent: Novartis Institutes For Biomedical Research, Inc.

20090182008 - Crystalline forms of pitavastatin calcium: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090182009 - Compositions and methods of treating retinal disease: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090182010 - Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity: wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, W, a and bare as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected... Agent: Theravance, Inc.

20090182011 - Chimeric nitrate esters and use of the same in a treatment for depression: Chimeric nitrate esters and their use in the treatment of depression are disclosed. The chimeric nitrate esters also are useful in the treatment of depression and comorbidity associated with aging.... Agent: Marshall, Gerstein & Borun LLP

20090182012 - Piperidin-2, 6-dione pamoate salts and their use for the treatment of affective disorders: Novel pamoate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression,... Agent: Bacon & Thomas, PLLC

20090182013 - Derivatives of 5-thioxylopyranose and use of same for treatment: The invention relates to new compounds of 5-thioxilose, preferably derivatives of the 5-thioxilopyranose type, and to a method for preparing the same and their use as the active ingredient of drugs mainly intended for treating or inhibiting thrombosis or heart failure or thromboembolic diseases.... Agent: Crowell & Moring LLP Intellectual Property Group

20090182014 - Insecticidal compositions comprising compounds having inhibitory activity versus acyl coa: cholesterol acyltransferase or salts thereof as effective ingredients: The present invention relates to insecticidal compositions comprising compounds having an inhibitory activity versus acyl CoA: cholesterol acyltransferase (ACAT) or salts thereof as effective ingredients. The compounds having inhibitory activity versus ACAT have an excellent insecticidal effect by inhibiting sterol metabolism in noxious insects. Therefore, the compounds of the present... Agent: Bozicevic, Field & Francis LLP

20090182015 - Microcapsule formulations: A method of producing microcapsule formulations wherein slurries containing imidacloprid suspended in water-immiscible organic solvents are wet-crushed, then, urethane-based macromolecular polymers are added to this, and the resultant mixture is dispersed as liquid drops in water, to form membranes on the interfaces of the liquid drops.... Agent: Birch Stewart Kolasch & Birch

20090182016 - Optical enantiomers of phenyramidol and process for chiral synthesis: The present invention discloses optically pure (R) and (S) Phenyramidol enantiomers and their pharmaceutically acceptable salts, a process for synthesising such enantiomers by means of a styrene oxide based asymmetric synthesis, and also a clinical evaluation of (R) and (S) enantiomers of Phenyramidol, their salts and compositions thereof for enhanced/newer... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090182017 - Pre-mixed, ready-to-use pharmaceutical compositions: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090182018 - Pre-mixed, ready-to-use pharmaceutical compositions: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090182019 - Histone deacetylase inhibitors: The present invention provides novel HDAC inhibitors and methods of treating diseases using the same.... Agent: Edwards Angell Palmer & Dodge LLP

20090182020 - Substituted bis(hetero)aromatic n--ethylpropiolamides and use thereof for production of medicaments: The present invention relates to substituted bis(hetero)aromatic N-ethylpropiolamides, methods for the production thereof, medicaments containing these compounds and the use thereof for the production of medicaments.... Agent: Norris, Mclaughlin & Marcus, Pa

20090182021 - Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to tricyclic compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of... Agent: Merck And Co., Inc

20090182022 - Treatment of fatty liver: Methods and compositions comprising peroxisomal and/or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty liver and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure. An active agent that by itself is associated... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090182023 - Tricyclic compound and pharmaceutical use thereof: t

20090182024 - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof: An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix, the matrix comprising at least two water swelling polymers, wherein one of the polymers is pregelatinized starch, and wherein another one of the polymers is an anionic polymer.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090182025 - Substituted carboxamides: This application relates to a substituted carboxamide compound of formula I, or a pharmaceutically acceptable salt thereof, as defined herein, a pharmaceutical composition thereof, and its use in treating pain.... Agent: Eli Lilly & Company

20090182026 - Alpha 2 adrenergic agonists: i

20090182027 - Methods of using [3.2.0] heterocyclic compounds and analogs thereof: Disclosed are methods of treating cancer, inflammatory conditions, and/or infectious disease in an animal comprising: administering to the animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent.... Agent: Knobbe Martens Olson & Bear LLP

20090182028 - Plant components and extracts and uses thereof: The present invention provides a medicament comprising a chemical compound according to formula A: wherein R1 is hydrogen, fluorine, chlorine, bromine, hydroxy, mercapto, methoxy, ethoxy, acetoxy, methyl, ethyl, propyl, isopropyl, t-butyl, nitro, amin, N,N-dimethylaminoyl, N,N-diethyl-aminoyl; R2 is hydrogen, a C1-8-alkyl e.g. methyl, ethyl, propyl, isopropyl, butyl, t-butyl; an C1-8-acyl e.g.... Agent: Chalker Flores, LLP

20090182029 - 2-indolinone derivatives as selective histone deacetylase inhibitors: e

20090182030 - Process for the preparation of amorphous calcium salt of atorvastatin: A process for the preparation of amorphous atorvastatin calcium. The process includes providing a reaction mixture having a pH between 6.5 and 8.0 containing a sodium salt of atorvastatin and tetrahydrofuran. A non-cyclic chlorinated organic solvent selected from the group consisting of dichloromethane, trichloroethane, tetrachloroethane and chloroform or addition of... Agent: Darby & Darby P.C.

20090182031 - Reduction of hair growth: Mammalian hair growth is reduced by topically applying a composition including a heat shock protein inhibitor.... Agent: Fish & Richardson P.C.

20090182032 - Companion animal compositions including lipoic acid and methods of use thereof: The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.... Agent: Colgate-palmolive Company

20090182033 - Cyclic amine derivatives and their uses: Compounds of formula (I) have muscarinic M3 receptor modulating activity; formula (I) wherein R1 is C1-C6-alkyl or a hydrogen atom; and R2 is a hydrogen atom or a group -R5 or a group, -Z-Y—R5, or a group -Z-NR9R10, or a group -Z-N(R9)C(O)R11; and R3 is a lone pair, or C1-C6-alkyl;... Agent: Fish & Richardson P.C.

20090182034 - Compositions and method for treating affective, painful or allergic disorders: Therapeutic compositions of doxepin and having a preponderance of the cis doxepin isomer over the trans doxepin isomer provide therapeutic effects for affective, painful, or allergic disorders without the sedative effects commonly experienced with compositions having a preponderance of the trans doxepin isomer.... Agent: Barnes & Thornburg LLP

20090182035 - Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis: Disclosed are methods of treating allergic conjunctivitis and non-infectious rhinitis in a subject that involve topically administering to the subject a composition comprising olopatadine and cilomilast.... Agent: Alcon

20090182036 - Animal food composition comprising genistein and polyunsaturated fatty acids: The invention relates to the use of nutraceutical compositions comprising as active ingredients genistein and at least one poly-unsaturated fatty acid for improving cognitive functions and/or for the treatment or prevention of age-related disorders in pets. The compositions are of primary interest for use in dog and cat food.... Agent: Nixon & Vanderhye, PC

20090182037 - Cognitive function: This invention relates to compositions containing polyphenols, for example, cocoa polyphenols such as flavanols and their related oligomers, and methods for treating abnormalities in gap junctional communication of cells, such as cancer, heart arrhythmia, neuro-degenerative diseases and cognitive dysfunction.... Agent: Nada Jain, P.C.

20090182038 - Leptomycin derivatives: Leptomycin derivatives having a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody are disclosed. The therapeutic use of such leptomycin derivative conjugates is also described; such conjugates have therapeutic use because they can deliver cytotoxic leptomycin derivatives to... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090182039 - Choline salt crystal of azulene compound: A choline salt crystal of (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol which shows an endothermic peak at 194 to 198° C. as measured by differential scanning calorimetry (DSC analysis) and shows main peaks at about 2θ (°) 5.58, 14.72, 16.80, 17.82, 21.02, and 22.46 as measured by X-ray powder diffraction. Thus, a crystal of an... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090182040 - Method of preventing or reducing insecticidal resistance: The present invention relates to a method of preventing or reducing insecticidal resistance of adult insect pests of the family Nitidulidae, the family Curculionidae and Psylliodes spp. which method comprises contacting the plant or the soil or water in which the plant is growing, or the pest or its food... Agent: Brinks, Hofer, Gilson & Lione

20090182041 - Control of cancer with annonaceous extracts: A crude extract composition derived from the plant family Annonaceae and the method for producing the crude extract composition. Medicinal benefits of the extract include tumor regression and the reduction of tumor antigen levels.... Agent: Stoel Rives LLP - Slc

20090182042 - Tiglien-3-one derivatives: The present invention relates to tiglien-3 -one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment.... Agent: Seed Intellectual Property Law Group PLLC

20090182043 - Pharmaceutical preparation of aqueous solution containing platinum complex: To provide an aqueous pharmaceutical preparation of a platinum complex which has no fear of contaminating a compounder with a drug with cytotoxicity, can be prepared by a simple operation, has a compact size, and is suppressed from deteriorating of drug during a long-term storage, an aqueous pharmaceutical preparation of... Agent: Kubovcik & Kubovcik

20090182044 - Nitrate amino acid chelates: The present invention is directed to methods and compositions which include nitrate amino acid chelates that can increase the metabolic activity or metal concentration in animals and that can increase metabolic activity and nitrogen content in plants. In one embodiment, a nitrate-complexed amino acid composition can comprise a metal, an... Agent: Thorpe North & Western, LLP.

20090182045 - Use of aminaphtone for the preparation of a medicament for treating arteriopathies: The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration.... Agent: Pearne & Gordon LLP

20090182046 - Cosmetic compositions containing esters based on 2-propylheptanol: Esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C36 carboxylic acids and C4-C36 dicarboxylic acids, compositions comprising these esters, and to the use of esters of 2-propylheptanol with linear or branched, saturated or unsaturated C5-C36-carboxylic acids and/or C4-C36-dicarboxylic acids in cosmetic and/or topical pharmaceutical preparations.... Agent: Fox Rothschild LLP

20090182047 - Utilization of dialkylfumarates: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in... Agent: Biogen Idec / Finnegan Henderson, LLP

20090182048 - Compounds useful for treating neurological disorders: The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090182051 - Cosmeceutical formulation containing palm oils: A cosmeceutical formulation is provided that includes a mixture of a refined, bleached, deodorized (RBD) palm oils and red palm olein. The resulting formulation is a homogeneous blend with a considerable shelf life. The formulation may be a cream, lotion, sunscreen, or a soap and may be formulated to include... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090182049 - Pharmaceutical composition and method for treating hypertriglyceridemia and hypercholesterolemia in humans: A method for the treatment or prophylaxis of hypertriglyceridemia and hypercholesterolemia without concomitantly increasing LDL-serum cholesterol, in a human subject requiring such treatment, which method comprises orally administering to the patient an effective amount of a pharmaceutical composition in which the active ingredients comprise a mixture of fatty acids, wherein... Agent: Jones Day (for Nordic Naturals)

20090182050 - Salts of fatty acids and methods of making and using thereof: Disclosed are methods of making salts of fatty acids (e.g., marine oils) and to salts prepared by the disclosed methods. Methods of using the disclosed salts are also disclosed.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090182052 - Taste-masked docusate compositions: A taste-masked liquid composition of docusate includes a docusate salt, povidone, a polyether, and water. Additional ingredients in the composition may include thickeners, sweeteners, flavorants, polyols, preservatives, chelating agents and pH adjusters. Such compositions may be used as taste-masked oral compositions of docusate, and may provide therapeutic effects such as... Agent: Evan Law Group LLC

20090182053 - Fenofibric acid amorphous dispersion; method of making; and method of use thereof: Disclosed are fenofibric acid amorphous dispersions containing amorphous fenofibric acid and an amorphous dispersion excipient. The amorphous dispersions can be prepared by e.g., spray drying techniques and formulated into pharmaceutical products.... Agent: Cantor Colburn, LLP

20090182054 - Topical compositions containing solubilized dicarboxylic acids: Topical compositions containing at least one solubilized dicarboxylic acid having 6 to 12 carbon atoms are prepared in pharmaceutically acceptable carriers in the presence of at least one 1,2-alkanediol having 5 to 7 carbon atoms. In particular, a topical composition containing solubilized azelaic acid is formulated in an aqueous carrier.... Agent: Jerry Zhang

20090182055 - Fungicidal agent containing n-chlorotaurine and use thereof: A fungicidal agent for treating infectious diseases caused by fungi contains N-chlorotaurine or one of its salts in aqueous solution, optionally with customary pharmaceutical additives.... Agent: Frederic P. Zotos

20090182056 - Pharmaceutical formulations of amyloid inhibiting compounds: Therapeutic formulations and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Therapeutic formulations and methods for preventing or treating amyloidosis and/or amyloid-related disease are also described.... Agent: Millen, White, Zelano & Branigan PC

20090182057 - Deuterated aminoglycidal compounds: Provided herein are substituted aminoglycidyl compounds of Formula (1), processes of preparation, and pharmaceutical compositions thereof and methods of their use for treating, preventing, or ameliorating one or more symptoms of a social anxiety disorder, an anxiety disorder, hyperthyroidism, tremor, glaucoma, hypertension, coronary artery bypass graft, chronic stable angina, atrial... Agent: Global Patent Group - Apx Ms. Lavern Hall

20090182058 - Novel chalcone derivatives with antimitotic activity: o

20090182059 - Injectable viscous medicinal preparation comprising ethanol and an x-ray opaque fat-soluble compound: This invention relates to an injectable medicinal preparation comprising ethanol and at least one at least partially X-ray opaque, fat-soluble compound, characterized in that it further comprises an ethanol-soluble compound which, when dissolved, has a viscosity ranging from 10 to 700 cP and preferably from 90 to 350 cP at... Agent: Young & Thompson

20090182060 - W/o/w type emulsified composition: i

20090182061 - Method for making comb polymers by drying then functionalization of the meth(acrylic)polymer backbone,resulting polymers and uses thereof:

20090182062 - Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to... Agent: Hoffmann & Baron, LLP

20090182063 - Rgd-enriched gelatine-like proteins with enhanced cell binding: The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at... Agent: Ip Patent Docketing K&l Gates LLP

  
07/09/2009 > patent applications in patent subcategories. category listing

20090176691 - Pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes: The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. Said pharmaceutical compositions contain said at least one protein active ingredient, in free form, as well as, for liquids, a system that buffers them to a pH greater than 4 and less... Agent: Keown & Zucchero, LLP

20090176692 - Amidated insulin glargine: The invention relates to insulin glargine which is modified by amidation, especially Gly (A21), Arg (B31), Arg amide (B32) human insulin (insulin glargine amide).... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090176693 - Agent for maintaining the hardness of tooth structure: Provided are an agent for maintaining hardness of tooth substances and a food or drink for maintaining the hardness of tooth substances, both of which include lactoferrin and iron-lactoferrin as an active ingredient. Lactoferrin and iron-lactoferrin suppress decalcification of enamel by use or ingestion thereof, and hence is effective for... Agent: Young & Thompson

20090176694 - Reagents and methods for smooth muscle therapies: The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090176695 - Reagents and methods for smooth muscle therapies: The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090176697 - Method to obtain the human chorionic gonadotropin (hcg)/cyclodextrin complex for oral administration, product obtained by this method and clinical and therapeutic use of the complex human chorionic gonadotropin (hcg)/cyclodextrin: e

20090176696 - Methods and compositions for modulating an immune response: The present invention provides compositions and methods for the suppression of Th2-mediated immune response. Tracheal cytotoxin is shown to mediate a selective suppression of T helper cell type 2 (Th2)-mediated immune responses. The methods and compositions of the invention are useful for the treatment of Th2-mediated diseases and conditions due... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090176698 - Benzimidazolone derivatives for the treatment of urinary incontinence: The invention relates to compositions comprising benzimidazolone derivatives of formula (I), optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof and methods of treating or preventing urinary incontinence, comprising the administration of a therapeutically effective amount of compound of formula (I),... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090176701 - Anti-microbial agents that interact with the complement system: Anti-microbial therapeutic agents that act via a novel method to treat infection are compounds which may comprise a peptide with natural or non-natural amino acids, or a small molecule. The agent can bind to the surface of a microorganism and productively fix complement in order to cause lysis of the... Agent: Novartis Corporate Intellectual Property

20090176708 - Chemically modified factor ix: The present invention discloses a chemically modified FIX, wherein the activation peptide region contains a covalently coupled water-soluble hydrophilic polymer.... Agent: Baxter Healthcare Corporation

20090176700 - Derivatives of glp-1 analogs: The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090176704 - Exendin agonist analogs to treat diabetes: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090176707 - Human signal peptide-containing proteins: The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP.... Agent: Foley And Lardner LLP Suite 500

20090176699 - Inhibitors based on fusion, hr1 and hr2 sequences in bacterial adhesin: A known surface adhesin (NadA) in Neisseria meningitidis contains sequences which correspond to the fusion peptide, HR1 repeat and HR2 repeat seen in the envelope protein of viruses. Fusion inhibitors may thus be used to inhibit meningococcal infection, and the invention provides a compound that can bind to the heptad... Agent: Novartis Vaccines And Diagnostics Inc.

20090176706 - Materials and methods for treatment of inflammatory and cell proliferation disorders: The present invention pertains to methods for treatment of inflammatory and cell proliferation disorders, such as cancer, by administering an agent that reduces atrial natriuretic peptide receptor-A (NPR-A) activity. In one aspect, the invention concerns a method for treatment of inflammatory and cell proliferation disorders, such as cancer, by administration... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090176705 - Modular platform for targeted therapeutic delivery: Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a dissociation constant Kd of less than about 10−7 M, and a pharmaceutically active moiety, wherein the targeting moiety is other than an oligopeptide,... Agent: Washington University-snr C/o Sonnenschein Nath & Rosenthal L.l.p

20090176703 - Neuropeptides for aquatic organisms culture: The present invention is related to the use of variants of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) to stimulate the growth and to improve the immunological system of aquatic organisms. The variants of the peptide were provided by immersion, injection or as a food additive.... Agent: Hoffmann & Baron, LLP

20090176709 - Process for obtaining a concentrate of von willebrand factor or a complex of factor viii/von willebrand factor and use of the same: The process is characterised by the preparation of a solution of Von Willebrand Factor or a complex of Factor VIII/Von Willebrand Factor which contains VWF and a concentration of up to 12 IU VWF:RCo/ml and a Von Willebrand Factor/Factor VIII ratio of 0.4 or more; and then proceeding with nanofiltration... Agent: Buchanan, Ingersoll & Rooney PC

20090176702 - Use of long-acting recombinant human soluble tumor necrosis factor alpha receptor in manufacture of a medicament for the treatment and/or prophylaxis of hepatic failure: The present invention belongs to the field of the application of genetic engineering and gene function, and it is directed to a new medical use of the gene encoding the recombinant soluble tumor necrosis factor α receptor (HusTNFR). The present invention made intervention to fulminant hepatic failure in mice by... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090176710 - Complex for transferring an anionic substance into a cell: The present invention relates to compositions and methods for the delivery of an anionic substance using complexes, comprising the anionic substance and a peptide. These complexes are useful for delivering said anionic substance into a cell, particularly in therapeutic applications.... Agent: Alnylam/fenwick

20090176711 - Inhibitors of amyloid precursor protein processing: Disclosed is a method of using a compound as an inhibitor for β-secretase, wherein the compound is capable of binding to the site within the β-secretase recognition and/or cleavage site on amyloid precursor protein to specifically inhibit the β-secretase's activity to cleave amyloid precursor protein with maintaining its activities to... Agent: Jhk Law

20090176713 - Co-administration of an agent linked to an internalization peptide with an anti-inflammatory: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results... Agent: Townsend And Townsend And Crew, LLP

20090176712 - Peptides with efficacy in rescuing melanocortin-4 receptor polymorphic agonist signaling: Disclosed are novel ligands based on an AGRP template that can rescue endogenous melanocortin agonist and/or antagonist dysfunction at MCR polymorphisms. In particular, the present invention provides novel synthetic ligands based on AGRP templates that can rescue endogenous melanocortin agonist dysfunction at MC4R polymorphisms to treat children and adults with... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090176716 - Inhibitors of cancer cell, t-cell and keratinocyte proliferation: s

20090176714 - Method of reducing the effects of abeta and compositions therefore: The invention provides methods and materials related to inhibiting the effects of Aβ such as neuronal cell death and tau phosphorylation. For example, the invention provides polypeptides, compositions containing polypeptides, transgenic animals, and methods for preventing an Aβ effect (e.g., neuronal cell death in a mammal).... Agent: Quarles & Brady LLP

20090176715 - Pharmaceutical compositions and methods utilizing a d-amino acid: The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.... Agent: Townsend And Townsend And Crew, LLP

20090176717 - Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be... Agent: Seed Intellectual Property Law Group PLLC

20090176718 - Berry preparations for treatment of diabetes and metabolic syndrome: The present invention provides a pharmaceutical composition for the treatment of a disordered metabolism syndrome comprising anthocyanin-rich extracts from berries. The present invention further provides a method for treating a disordered metabolism syndrome utilizing anthocyanin-rich extracts from berries.... Agent: Cozen O''connor

20090176719 - Compositions and methods for treating perioral dermatitis: Methods for treating perioral dermatitis are described herein. The method includes administering topically a composition containing an effective amount of a systemic or topical antibiotic and a corticosteroid. The concentration of the antibiotic is from about 0.01% to about 5% by weight of the composition and the concentration of the... Agent: Pabst Patent Group LLP

20090176720 - Compositions containing piperacillin and tazobactam useful for injection: An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that... Agent: Wilmerhale/wyeth

20090176721 - Nucleoside analogs with carboxamidine modified monocyclic base: Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects... Agent: Mcdermott, Will & Emery

20090176725 - Chemically modified short interfering nucleic acid molecules that mediate rna interference: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20090176727 - Double-stranded rna structures and constructs, and methods for generating and using the same: The present invention relates to novel double-stranded RNA (dsRNA) structures and dsRNA expression constructs, methods for generating them, and methods of utilizing them for silencing genes. Desirably, these methods specifically inhibit the expression of one or more target genes in a cell or animal (e.g., a mammal such as a... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090176729 - Method of treating neurodegenerative disease: Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells.... Agent: Lowrie, Lando & Anastasi, LLP

20090176724 - Methods and compositions for the diagnosis, prognosis and treatment of cancer: The invention is relates to splice variants of basal transcription factors and other transcriptional modulators, the use of expression analyses of the same as a diagnostic and prognostic tool, and the targeting of such splice variants for therapeutic purposes, particularly in relation to the treatment of cancer.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090176723 - Methods and compositions involving mirna and mirna inhibitor molecules: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors... Agent: Fullbright & Jaworski L.L.P.

20090176726 - Methods for treating mitf-related disorders: Methods for treating melanoma and other MITF-related disorders by administering a compound that causes an increase in HIF-1 level or activity (e.g., by increasing the level of HIF-1I in a cell) within cells. Such methods include administration of a compound that is a hydroxylase inhibitor, e.g., a prolyl hydroxylase inhibitor... Agent: Fish & Richardson PC

20090176728 - Treatment of cns conditions: Methods and compositions for the treatment of pathologic conditions of the central nervous system (CNS) by means of intranasal administration of a composition that modulates, by means of RNA interference, the expression and/or activity of genes involved in above-mentioned conditions.... Agent: King & Spalding

20090176731 - Combination therapy of cancer with azd2171 and gemcitabine: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20090176730 - N4-acylcytosine nucleosides for treatment of viral infections: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives... Agent: Merchant & Gould PC

20090176732 - Protected nucleotide analogs: Disclosed herein are nucleotide analogs with one or more protecting groups, methods of synthesizing nucleotide analogs with one or more protecting groups and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with one or more protecting groups.... Agent: Knobbe Martens Olson & Bear LLP

20090176734 - Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants: The present invention is directed to a novel method for increasing the production of acetate, decreasing the production of butyrate, increasing the population and species of beneficial bacteria and slowing the rate of fermentation of prebiotics within the gut of a formula-fed infant. The method comprises administration of a therapeutically... Agent: Waddey & Patterson, P.C.

20090176733 - Novel medicaments for anti-herpes virus treatments: The invention concerns the use of a sulphated or phosphated polysaccharide for preparing a drug for treating herpes virus mediated diseases, more particularly mediated by alpha-herpes viruses, and in particular by HSV-1 and HSV-2, as well as by strains of those viruses which are resistant to known antiviral agents. The... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090176736 - Pharmaceutical composition for conformational diseases: e

20090176735 - Preventing or reducing oxidative stress or oxidative cell injury: A water-soluble cellulose derivative is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for regulating Stearoyl-CoA Desaturase-1 gene expression and/or ATPF1 gene expression in non-adipose tissues of the animal.... Agent: The Dow Chemical Company

20090176737 - Composition for soft contact lens and adsorption suppressing method: Disclosed is a composition for soft contact lenses which enables to suppress adsorption of a basic chemical substance onto a soft contact lens. This composition for soft contact lenses comprises (A) a basic chemical substance selected from amines having a secondary amino group and/or a tertiary amino group and salts... Agent: Birch Stewart Kolasch & Birch

20090176738 - Dermal medicament delivery system: There is provided a means of applying a heated medicament to the skin and concurrently hydrating the skin thus raising the efficacy of administration.... Agent: Omri M. Behr

20090176739 - Optical isomers of an iloperidone metabolite: The present invention relates to novel isomers of a metabolite of Iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.... Agent: Hoffman Warnick LLC

20090176740 - Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine: Aniracetam (1-[(4-methoxybenzoyl)]-2-pyrrolidinone) is co-administered with the acetylcholine precursor 1-alpha glycerylphosphorylcholine (Alpha GPC, choline alfoscerate, choline alphoscerate) to potentiate cognition enhancing effects in healthy subjects and patients suffering from neurological conditions including Alzheimer's Disease (AD), attention deficit disorder (ADD), Parkinson's Disease, schizophrenia, vascular dementia, post stroke aphasia, anxiety disorders, cerebral atrophy,... Agent: Douglas J. Phillips Ii

20090176741 - Modulation of the immune system by inositol phospholipids: The invention relates to the field of immunology. More specifically, it relates to methods and compositions to suppress the immune system, among other by interference with antigen-presenting molecules and T-cell activation. Provided is a composition for the prevention or treatment of a condition wherein suppression of T cell activation is... Agent: Rissman Hendricks & Oliverio, LLP

20090176743 - Methods for treating or preventing reactivation of a latent herpesvirus infection: The invention is directed to methods and compositions for treating or preventing reactivation of a latent herpesvirus infection and the associated complications and outcomes. The methods involve administering a composition comprising glutamine, or a derivative, conjugate, or analog thereof.... Agent: Clark & Elbing LLP

20090176742 - Methods relating to the treatment of fibrotic disorders: The invention provides α-mimetic structure of formula (I), wherein A is —(C═O)—(CHR3)— or —(C═O)—; B is —(NR5)— or —(CHR6)—; D is —(C═O)—(CHR7)— or —(C═O)—; E is -(ZR8)— or —(C═O)—, where Z is nitrogen or CH; —(XR9)n—, —(CHR10)—(NR6)—, —(C═O)—(XR12)—, —(C═N—W—R1)—, —(C═O)—, —(X—(C═O)—R13)—, —(X—(C═O)—NR13R14)—, —(X—(SO2)—R13)—, or —(X—(C═O)—OR13)—, where X is nitrogen or... Agent: Nixon Peabody LLP - Patent Group

20090176722 - Androgen-regulated pmepa1 gene and polypeptides: This invention relates to the androgen-regulated gene, PMEPA1, and proteins encoded by this gene, including variants and analogs thereof. Also provided are other androgen-regulated nucleic acids, a polynucleotide array containing these androgen-regulated nucleic acids, and methods of using the polynucleotide array in the diagnosis and prognosis of prostate cancer.... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP

20090176744 - Deuterated fingolimod: This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090176745 - Triarylmethane analogs and their use in treating cancers: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases,... Agent: Intellectual Property / Technology Law

20090176746 - Thrombopoietin mimetics: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090176747 - Tetracycline compounds and methods of treatment: The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20090176748 - Methods and compositions for controlled release oral dosage of a vitamin d compound: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin... Agent: Marshall, Gerstein & Borun LLP

20090176749 - Oil-in-water emulsion lotion containing 22-oxa-1alpha, 25-dihydroxyvitamin d3 and method of treatment of skin disorder using the same: Provided is a lotion that exhibits high percutaneous absorption inherent in maxacalcitol, allows the maxacalcitol to be stable, and exhibits less dripping when it is applied to heads. A basic oil-in-water emulsion lotion containing 22-oxa-1α,25-dihydroxyvitamin D3, medium-chain triglyceride, a nonionic surfactant, and a water-soluble thickener and a method of treatment... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090176750 - Compositions and methods for enhancing corticosteroid delivery: The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and... Agent: Reed Smith LLP

20090176751 - Combinations comprising antimuscarinic agents and beta-adrenergic agonists: A combination which comprises (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.... Agent: Hoxie & Associates LLC

20090176752 - Diene compounds and formulations: The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it... Agent: Hollis-eden Pharmaceuticals, Inc.

20090176753 - Betulinol derivatives as anti-cancer agents: The present invention relates to a method of treating cancer selected from the group of cancers consisting of prostate cancer, renal cancer, breast cancer, ovarian cancer, CNS cancer, melanoma, lung cancer, and bladder cancer. This method involves administering to a patient in need of such treatment a therapeutically effective amount... Agent: Marshall, Gerstein & Borun LLP

20090176754 - Crystalline form of the compound a-348441: There is provided a hemihydrate of (3β, 5β, 7α, 12α)-7,12-dihydroxy-3-{2-[{4-[17β-hydroxy-3-oxo-17α-prop-1-ynylestra-4,9-dien-11β-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2θ=6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090176755 - Pharmaceutical compositions comprising an antibiotic: The present invention relates to cefdinir. More particularly to pharmaceutical formulations comprising cefdinir in a defined polymorphic form and processes for the preparation thereof. Furthermore, the present invention relates to processes to keep cefdinir in a defined polymorphic form.... Agent: Novartis Corporate Intellectual Property

20090176756 - Substituted thiazoles and their use for producing drugs: The present invention relates to substituted thiazoles, to methods for the production thereof, to medicaments containing these compounds and to the use thereof for producing medicaments.... Agent: Norris, Mclaughlin & Marcus, Pa

20090176757 - Bicyclic spirohydantoin cgrp receptor antagonists: (wherein variables A1, A2, A3, A4, A5, A6, A7, B, E1, E2, E3, E4, E5, G1, G2 and R6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The... Agent: Merck And Co., Inc

20090176758 - Lactam-containing compounds and derivatives thereof as factor xa inhibitors: h

20090176759 - Leukemic stem cell ablation: A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.... Agent: Morgan, Lewis & Bockius, LLP

20090176760 - Tricyclic compounds: (wherein R1 represents lower alkyl optionally having substituent(s) or the like, R2 and R3 are the same or different and each represents lower alkyl optionally having substituent(s) or the like, R4 and R5 are the same or different and each represents a hydrogen atom or the like, Q1-Q2-Q3 represents CH═CH—CH═CH... Agent: Leydig Voit & Mayer, Ltd

20090176762 - Jnk inhibitors for treatment of skin diseases: This invention relates to the use of a JNK inhibitor for treating and/or preventing skin diseases selected from psoriasis and dermatitis.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090176761 - Jnk inhivitors for the treatment of endometriosis: This invention relates to a method of treating and/or preventing endometriosis comprising administering a JNK inhibitor. The JNK inhibitor can also be administered combined with a hormonal suppressor. The invention further relates to the treatment of endometriosis-related infertility... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090176763 - Azaindoles useful as inhibitors of jak and other protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20090176764 - 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents: which are useful in treating osteoporosis, acne, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, adenomyosis, infertility, endometriosis, endometrial cancer, polycystic ovary syndrome, cardiovascular disease, Alzheimer's disease, cognitive decline, central nervous system disorders, central nervous system cancers, leukemia, endometrial ablations, chronic renal disease, chronic hepatic disease, coagulation diseases and disorders,... Agent: Howson & Howson LLP / Wyeth

20090176767 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, p, r, R1, R2, R3, R4, R5, R6, W and X1 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of... Agent: Theravance, Inc.

20090176768 - Diaza heterocyclic amide compounds and their uses: e

20090176766 - Imidazolidinone and imidazolidinethione derivatives:

20090176765 - Pyridinone and pyridazinone derivatives as inhibitors of poly (adp-ribose) polymerase (parp): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced... Agent: Merck And Co., Inc

20090176769 - Cgrp receptor antagonists: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.... Agent: Vertex Pharmaceuticals Inc.

20090176771 - Gyrase inhibitors and uses thereof: The present invention relates to compounds which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.... Agent: Vertex Pharmaceuticals Inc.

20090176770 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: wherein A, X, D, E, G, M, Q and R1 to R3 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090176772 - Method of reversing left ventricular remodeling: The present invention relates to method of reversing left ventricle remodeling by combined administration of therapeutically effective amounts ranolazine and at least one co-remodeling agent, which may be an ACE inhibitor, an ARB, or a beta-blocker. The method finds utility in the treatment of heart failure. This invention also relates... Agent: Cv Therapeutics, Inc.

20090176774 - Compounds and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20090176775 - Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use: wherein i, j, n, o, p, q, r, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b and R4 are as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090176773 - Non-peptidic inhibitors of akap/pka interaction: The invention relates to non-peptidic molecules which modulate, especially inhibit, the interaction of protein kinase A (PKA) and A kinase anchor proteins (AKAP) and to a host or target organism that comprises said non-peptidic compounds or recognition molecules directed to said compounds, such as e.g. antibodies or chelating agents. The... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090176776 - Small molecule inhibitors of hiv-1 capsid assembly: The present invention provides novel methods of treating HIV infections employing small molecule inhibitors identified by chemical library (DIVERSet™ library). These small molecule inhibitors may specifically bind to HIV-1 capsid protein thereby interfering with capsid assembly. The small molecule inhibitors of the present invention can be potential drug targets in... Agent: Nixon Peabody, LLP

20090176778 - Certain nitrogen containing bicyclic chemical entities for treating viral infections: Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).... Agent: Glaxosmithkline C/o Foley & Lardner LLP

20090176777 - Imidazo (1,2-a)pyridin-3-yl-acetic acid hydrazides, proesses for their preparation and pharmaceutical uses thereof: The invention provides novel imidazo[1,2-a]pyridin-3-yl-acetic acid hydrazides of formula (I) wherein R1, R2 and R3 have different meanings, and pharmaceutically acceptable salts, polymorphs, hydrates, tautomers, solvates and stereoisomers thereof. Compounds of formula (I) are useful for treating or preventing, in a human or non-human mammal, diseases associated with GABAA receptors... Agent: Birch Stewart Kolasch & Birch

20090176779 - Pyrazolo[4,3-d]thiazole derivatives, and preparation and therapeutic application thereof: e

20090176780 - Nitrogenous heterocyclic compounds: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the... Agent: Townsend And Townsend And Crew, LLP

20090176781 - Acetylenic heteroaryl compounds: e

20090176782 - Inhibitors of tace: The present invention relates to compounds that inhibit TACE, compositions thereof, and methods of using those compounds and compositions for treating diseases.... Agent: Vertex Pharmaceuticals Inc.

20090176783 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.... Agent: Paul D. Yasger Abbott Laboratories

20090176784 - Anti-infective agents and uses thereof: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts,... Agent: Paul D. Yasger Abbott Laboratories

20090176785 - Method of treating arthritis: Methods of preventing or treating arthritis is disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090176786 - Benzoylurea compounds and use thereof: wherein, X and Y represent a fluorine atom or a chlorine atom, R1 represents a lower alkyl group or the like, R2 represents a lower alkyl group, R3 represents a halogen atom or the like, R4 represents an alkylthio group optionally substituted with one or more of halogen atoms, or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090176787 - Crystalline forms of lamotrigine: The invention is directed to novel crystalline forms of lamotrigine. These novel crystalline forms of lamotrigine have improved dissolution and in-vivo absorption profile, as compared to pure lamotrigine. These novel crystalline forms of lamotrigine provide a substantial increase in the blood concentration of lamotrigine, as compared to pure lamotrigine when... Agent: Rakoczy Molino Mazzochi Siwik LLP

20090176788 - Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions: e

20090176789 - Diazaspirodecane orexin receptor antagonists: The present invention is directed to diazaspirodecane compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck And Co., Inc

20090176790 - Pterin analogs: Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.... Agent: Jones Day

20090176791 - Diaryl ureas for treating pulmonary hypertension: The present invention relates to pharmaceutical compositions for treating, preventing or managing pulmonary hypertension comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.... Agent: Edwards Angell Palmer & Dodge LLP

20090176792 - Substituted dibenzhydrylpiperazines: The present invention relates to new dibenzhydrylpiperazine modulators of histamine receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20090176793 - 3-(l,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-l-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist: 3-(1,3-Benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)pyridazine and salts and solvates thereof, (I) having histamine H3 antagonistic activity can be used in pharmaceutical compositions.... Agent: High Point Pharmaceuticals, Inc.

20090176794 - 1h-indol-1-yl-urea compounds: (

20090176795 - Enhanced delivery of antifungal agents: Tetrahydrofuran antibiotics formulated with certain diacylglycerol-poltethyleneglycol (DAG-PEG) lipids have increased water solubility and bioavailabilty. PEG-12 GDO, PEG-12 GDLO, PEG-12 GDM and PEG-12 GDP are particularly suitable for forming liposomes that incorporate tetrahydroflurans in the bilayer.... Agent: Lee Pederson

20090176797 - Pharmaceutical composition for treating esophageal cancer: [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered... Agent: Sughrue Mion, PLLC

20090176798 - New compounds iii: 1

20090176796 - Trpv1 antagonists including amide substituent and uses thereof: and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA″ or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount... Agent: Dechert LLP

20090176799 - Phosphodiesterase 4 inhibitors: d

20090176800 - In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia:

20090176801 - Novel lapachone compounds and methods of use thereof: The invention provides lapachone analogs and derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can also be used in the treatment or prevention of cancer or precancerous conditions.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090176802 - Antidotes to exogenous neurotoxic agents: A novel method for treating a mammal exposed to an exogenous neurotoxic agent is disclosed.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090176803 - Cinnamoyl-piperazine derivatives and their use as par-1 antagonists: n

20090176804 - 2-phenyl-indoles as prostaglandin d2 receptor antagonists: The present invention is directed to 2-phenyl-indole compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090176805 - Derivatives of ethylene methanedisulfonate as cancer chemotherapeutic agents: The present application discloses derivatives of ethylene methanedisulfonate as cancer chemotherapeutic agents and methods of synthesizing such derivatives. The derivatives include modifications of ethylene methanedisulfonate by replacing one or both of the chemically most reactive hydrogens of the cyclic sulfonate ester structure. The derivatives of ethylene methanedisulfonate are more active... Agent: Alleman Hall Mccoy Russell & Tuttle LLP

20090176806 - Substituted pyrroline kinase inhibitors: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.... Agent: Philip S. Johnson Johnson & Johnson

20090176807 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof: wherein R1, R2, R3, R4, R5, R6 and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090176808 - combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist: The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse... Agent: Darby & Darby P.C.

20090176809 - Raf inhibitor compounds and methods: Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Viksnins Harris & Padys Pllp

20090176810 - Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin: The present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient. More particularly, the composition for external skin application comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR-α), to stimulate expression... Agent: Nixon & Vanderhye, PC

20090176811 - Substituted 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydro-quinazoline-2-yl compounds: e

20090176812 - Heteromonocyclic compound and use thereof: R3 and R4 are each H, or C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylamino, di(C1-C6)alkylamino or C1-C6 alkylthio, each of which is optionally substituted; and R5 is H, or C1-C6 alkyl, C2-C6 alkenyl, cyclic group, each of which is optionally substituted, —CO—R8 or —O—R8′, or a salt thereof. The... Agent: Foley And Lardner LLP Suite 500

20090176813 - Aqueous suspensions of tmc278: This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection.... Agent: Philip S. Johnson Johnson & Johnson

20090176814 - Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains: The invention relates to pharmaceutical combinations of potassium channel openers and sodium channel inhibitors. for treating pains which are accompanied by an increase in muscle tone.... Agent: Mcdermott, Will & Emery

20090176815 - Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity: Compounds of formula (I) wherein R1, R3, R4, R5, R6, R7, and R10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the... Agent: Fish & Richardson P.C.

20090176816 - Drug composition for treating 2 type diabetes and diabetic chronicity complications: A drug composition for treating type 2 diabetes and diabetic chronicity complications is disclosed. The composition is composed of mangiferin and berberine in a certain ratio. The composition has a preferable hypoglycemic and hypolipidemic effect compared with mangiferin and berberine which is used alone... Agent: Staas & Halsey LLP

20090176817 - Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject: A method of improving stool frequency in a subject having diarrhea-predominant IBS, comprising administering a composition comprising cilansetron or a pharmaceutically acceptable derivative thereof to a subject in need of treatment in an amount sufficient to decrease stool frequency within 2 days or less of administering.... Agent: Mayer Brown LLP

20090176818 - Antitussive agent: An antitussive, which can be used for therapy or prophylaxis of coughing, is disclosed. The antitussive comprises as an effective ingredient a morphinan derivative having a nitrogen-containing cyclic substituent or a pharmaceutically acceptable acid addition salt thereof, having a specific structure, such as the compound below [N-(17-cyclopeopylmethyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6β-yl)-3,4,5,6-tetrahydrophthalimide]. The antitussive has... Agent: Birch Stewart Kolasch & Birch

20090176819 - 39-desmethoxy-39-methyl derivatives of rapamycin: The present invention relates to novel 39-desmethoxy-39-methylrapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 39-desmethoxy-39-methylrapamycin derivatives in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft... Agent: Wyeth Patent Law Group

20090176820 - Polymorphic forms and process: e

20090176821 - Amide and carbamate derivatives of alkyl substituted n-[4-(4-amino-1h-imidazo[4,5-c] quinolin-1-yl)butyl]methanesulfonamides and methods: Amide and carbamate derivatives of N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamides with an ethyl, methyl, or n-propyl substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, and methods of use of these compounds in modulating the immune system, for inducing cytokine biosyn-thesis in animals and in the treatment of diseases... Agent: Wolf Greenfield & Sacks, P.C.

20090176822 - Pyrrolidine inhibitors of iap: i

20090176823 - Secondary amines as renin inhibitors: The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their... Agent: Hoxie & Associates LLC

20090176824 - 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field: e

20090176825 - Prolyl hydroxylase inhibitors:

20090176826 - Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects: wherein R is cycloalkyl, A is lower alkylene, and the bond between 3- and 4-positions of carbostyril nucleus is single bond or double bond, or a salt thereof and Probucol, which is useful for preventing and treating cerebral infarction including acute cerebral infarction and chronic cerebral infarction, arteriosclerosis, renal diseases... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090176827 - Maleate salts of (e)-n--4-(dimethylamino)-2-butenamide and crystalline forms thereof: The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.... Agent: Wyeth Patent Law Group

20090176828 - 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists: where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors. Additionally some of the claimed compounds have no or only minimal cardiovascular and/or... Agent: Allergan, Inc.

20090176829 - Bicyclic heteroaryl compounds as pde10 inhibitors: The invention pertains to tricyclic heteraaryi compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDE 10. The invention further relates to pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous... Agent: Pfizer Inc Mary J Hosley

20090176830 - Tartrate salt of isofagomine and methods of use: A novel tartaric acid salt of Isofagomine (Isofagomine tartrate) that can be used for the treatment of Gaucher disease is provided. The invention also provides a crystalline form of isofagomine tartrate, method for preparing the salt, a pharmaceutical composition containing the salt, and a method of treating Gaucher disease.... Agent: Hoffmann & Baron, LLP

20090176831 - Compounds and methods for treating cancer and diseases of the central nervous system: compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20090176832 - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Jones Day

20090176833 - Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary... Agent: Theravance, Inc.

20090176834 - Sublingual fentanyl spray: The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.... Agent: Snell & Wilmer L.L.P. (main)

20090176835 - Pharmaceutical composition for suppression of the expression of atp citrate lyase and use thereof: The present invention provides a pharmaceutical composition for suppression of the expression of ATP citrate lyase, which contains a compound that suppresses the expression of ATP citrate lyase by the in vivo administration. The compounds suppress the expression of ATP citrate lyase by the in vivo administration include insulin secretagogues... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090176837 - Compounds with activity at retinoic acid receptors: Disclosed herein are novel compounds with activity at RARβ 2 receptors. Further disclosed are the use of such compounds for treatment of or to alleviate symptoms of cancer, neurological disorders such as memory deficits and schizophrenia, neurodegenerative disorders such as Parkinson's and Alzheimer's diseases, inflammatory disorders such as psoriasis and... Agent: Knobbe Martens Olson & Bear LLP

20090176836 - Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck And Co., Inc

20090176838 - Cyclourea compounds as calcium channel blockers: The invention relates to cyclourea compounds of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1-R3 and Z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat, prevent or ameliorate a disorder responsive... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090176839 - Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid: The present invention relates to formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, pharmaceutical packs or kits thereof, and methods of treatment therewith.... Agent: Vertex Pharmaceuticals Inc.

20090176841 - Novel 6-5 system bicyclic heterocyclic derivative and its pharmaceutical utility: is a single bond or a double bond; A is —CH2— or —CO—; X, Y, and Z are each independently a nitrogen atom or a carbon atom; R1 is a hydrogen atom or an aralkyl group; R2 is an alkyl group or an aralkyl group, etc.; R3 is a hydrogen... Agent: Dardi & Associates, PLLC

20090176840 - Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods: This invention is directed to indolone derivatives which are antagonists or the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090176842 - Substituted arylsulfonamides as antiviral agents: The invention relates to substituted arylsulfonamides of formula (I) and methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses.... Agent: Morrison & Foerster LLP

20090176844 - Carboxamides: e

20090176843 - Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors: The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.... Agent: K&l Gates LLP

20090176845 - Substituted 2-aminotetralin derivatives as selective alpha 2b agonist: e

20090176847 - Dicyclooctane derivatives, preparation processes and medical uses thereof: The present invention relates to new dicyclooctane derivates represented by general formula (I), preparation processes and pharmaceutical compositions containing them, and to uses for treatment especially for dipeptidyl peptidase inhibitor (DPPIV), in which each substituent group of general formula (I) is as defined in specification.... Agent: Bingham Mccutchen LLP

20090176846 - N-hydroxy-4- {5- [4- (5-isopropyl-2-methyl-1, 3-thiazol-4-yl) phenoxy] pentoxy} benzamidine 2 methanesulfonic acid salt: Disclosed is an N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 methansulfonic acid salt, which has excellent bioavailability. Also disclosed are a method of preparing the compound and a pharmaceutical composition comprising the compound.... Agent: Medlen & Carroll, LLP

20090176848 - Fortifier: An agent for enhancing therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases is disclosed, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.... Agent: Ip Group Of Dla Piper US LLP

20090176849 - Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives: The invention relates to a new process for the preparation of sartans 2-butyl-3-[[2′-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one is disclosed, which proceeds via novel intermediate, 4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]phenylboronic acid (Formula (II)) or its analogs. Compound (II) reacts with 5-(2-bromophenyl)-1-(triphenylmethyl)-1H-tetrazole (III) in the presence of catalyst, using conditions of Suzuki reaction, to give trityl irbesartan (I), whereas analogs... Agent: Arent Fox LLP

20090176850 - Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia: This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20090176851 - Use of spiro [imidazolidine-4, 3' -indole] 2, 2', 5' (1h) triones for treatment of conditions associated with vanilloid receptor 1: The present invention relates to a new use of spiro-hydantoin derivatives of formula (I), or salts, solvates or solvated salts thereof, as well as to new compounds, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said therapeutically active compounds and to the... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090176852 - Processes of making and using pharmaceutical formulations of antineoplastic agents: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090176853 - Adamantane derivatives: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).... Agent: Morgan Lewis & Bockius LLP

20090176854 - Pyrazole derivatives, compositions containing such compounds and methods of use: Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20090176855 - Treatment of bipolar disorders and associated symptoms: r

20090176856 - Muscarinic receptor antagonists: This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed... Agent: Ranbaxy Inc.

20090176857 - Use of organic compounds: The invention relates to a pharmaceutical composition, use, or method in the treatment of Irritable Bowel Syndrome (IBS) characterized by mixed or alternating bowel habits based on a modification of the Rome II criteria (IBS-M), with 5-hydroxytryptamine type-4 receptor agonists (5-HT4 agonists), in particular tegaserod.... Agent: Novartis Corporate Intellectual Property

20090176858 - Hcv protease inhibitors and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Patent Department Choate, Hall & Stewart LLP

20090176859 - Cathepsin cysteine protease inhibitors: The present invention relates to a novel class of compounds mainly, leucinamide-amino-carboxylate derivatives of formula (I) wherein Y is CR1R2, O, S, —SO2, C=0 or NR9; Z is CR1R2, O, S, —SO2, C═O or NR9 and each G is independently a CR1CR2. Said compounds are cathepsin cysteine protease inhibitors, including... Agent: Merck And Co., Inc

20090176860 - Zofenopril calcium: The present invention relates to zofenopril calcium form A substantially free of other forms of zofenopril calcium and to zofenopril calcium having a chemical purity of more than 98.5%. The present invention also relates to methods of preparing such zofenopril calcium. It further relates to compositions comprising such zofenopril calcium.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090176861 - Cathepsin cysteine protease inhibitors: The present invention relates to a novel class of compounds mainly, substituted leucinamide-carboxylate derivatives of formula (I) wherein X is O or NR9, Y is CR1R2, —SO2, C═O or NR9; Z is CR1R2, O, S, —SO2 or NR9 and each G is independently a CR1CR2 and pharmaceutical compositions thereof. Said... Agent: Merck And Co., Inc

20090176862 - Methods for treating chemotherapy and radiation therapy side effects: A method for treating chemo therapy or radiation therapy side effects in a mammal undergoing chemotherapy and/or radiation therapy, the method comprising a step of administering to the mammal a therapeutically effective amount of a RAR antagonist or RAR inverse agonist which binds to receptors of the RARα, RARβ and... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090176863 - Thiophene derivative ppar modulators: The present invention is directed to compounds represented by the following structural formula, Formula I: and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) X is selected from the group consisting of O, S, S(O)2, N, and a bond; (b) U is an aliphatic linker wherein one carbon... Agent: Eli Lilly & Company

20090176864 - Methods for improving hepatic and immune function in an animal: The invention encompasses compositions and methods for improving animal health and in certain embodiments to compositions and methods for improving hepatic and immune function in aged felines.... Agent: Colgate-palmolive Company

20090176865 - Sulfamide derivative useful for the treatment of epilepsy: The present invention is directed to novel sulfamide derivatives, pharmaceutical compositions comprising said compounds and methods for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, said compounds, either alone or as co-therapy with one or more anticonvulsant and/or anti-epileptic agents.... Agent: Philip S. Johnson Johnson & Johnson

20090176868 - Amidoacetonitrile derivatives: The invention relates to compounds of the general formula (I) wherein X, Y and W have the significances given in claim 1 and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling parasites in and on warm-blooded animals.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090176866 - Complexes having adjuvant activity: A complex that comprises a narrow molecular weight distribution polymer that includes units derived from an acrylic acid or a salt thereof, and (i) a substance that has pharmacological activity against a pathogenic organism, or (ii) a substance that has pharmacological activity against a cancer, or (iii) one or more... Agent: Bell & Associates

20090176867 - Use of n-(dibenz(b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-ynylamine or a pharmaceutically acceptable addition salt thereof for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen vi deficiency: c

20090176869 - Halogenated rhodamine derivatives and applications thereof: in which one of R1, R2, R3, R4 and (R10)n represents halogen and each of the remaining R1, R2, R3, R4 and R10 groups is independently selected from hydrogen, halogen, amino, acylamino, dialkylamino, cycloalkylamino, azacycloalkyl, alkylcycloalkylamino, aroylamino, diarylamino, arylalkylamino, aralkylamino, alkylaralkylamino, arylaralkylamino, hydroxyl, alkoxy, aryloxy, aralkyloxy, mercapto, alkylthio, arylthio, aralkylthio,... Agent: Crowell & Moring LLP Intellectual Property Group

20090176870 - Tgf-beta modulators and methods for using the same:

20090176871 - Treatments for domestic animals having sex hormone deficiencies using soy germ isoflavones: The novel applicability and methods of use of soy germ extracted isoflavones for the treatment of sex hormone loss due to spaying, neutering and aging in domestic pets as well as service and guide animals.... Agent: Edward C. Schewe

20090176872 - Carotenoid composition and method for protecting skin: A method for protecting skin against damages caused by ultra-violet (uv) radiation from the sun, comprising administering to a subject in need of protection an effective amount of a composition containing lycopene from a natural source and one or more carotenoid selected from among phytoene and phytofluene or mixtures thereof.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090176873 - Novel use of organic compounds: wherein the clotted line is an optional bond; R1 is butyl or butyryl if R2 is hydroxyl but is butyl if R2 is hydrogen; or R1 and R2 taken together are 1-butylidene optionally substituted by hydroxyl, methyl, or 3-(α,β-dimethylacrylyloxy)-pentylidenyl; X is a residue selected from the group consisting of X1,... Agent: Nixon & Vanderhye, PC

20090176874 - Tnp-470 polymer conjugates and use thereof: The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular... Agent: David S. Resnick

20090176876 - Compositions, kits and regimens for the treatment of skin, especially decolletage: Compositions, kits and regimens for treatment of damaged skin, especially décolletage, include application of a retinoid, hydroquinone or hydroquinone derivatives, and a composition containing a multi-metal complex.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20090176875 - Method for manufacturing metal nano particle solution: A method for manufacturing a stabilized metal nano particle solution is disclosed. This method manufactures a metal nano particle solution so as to make a metal substance such as silver, gold, copper, zinc or cobalt into ultra-capsular nano particles. That is to say, this new method is simple and suitable... Agent: Park Law Firm

20090176877 - Oseltamivir phoshate granule and preparation method thereof: The present invention relates to an oseltamivir phosphate granule and preparation method thereof. The said granule comprises 1.97-19.8 wt. % oseltamivir phosphate, 75.0-97.5 wt. % diluent, 0.1-5.0 wt. % binder, optionally 1.0-5.0 wt. % edible flavouring essence, sweetener and/or edible pigment. It is prepared by using 30-55 v/v % aqueous... Agent: Christie, Parker & Hale, LLP

20090176878 - Genetic polymorphisms and substance dependence: The invention encompasses a method for identifying subjects at risk for substance dependence by detecting the presence of polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene. The invention also encompasses determining the response of a subject to a therapeutic substance, treating substance dependence in a subject, and evaluating... Agent: Polsinelli Shughart PC

20090176879 - Fatty acid desaturases from primula: The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes... Agent: Sonnenschein Nath & Rosenthal LLP

20090176880 - Methods for culturing human lung mast cells and uses thereof: Methods for culturing human lung mast cells in the absence of co-culture with feeder cells which are viable for longer than 4 days are provided. Also provided are methods for using these human lung mast cell cultures to assess biological and pharmacological activities of these cells in vivo and to... Agent: Licata & Tyrrell P.C.

20090176882 - Gastric retentive gabapentin dosage forms and methods for using same: Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of... Agent: King & Spalding LLP

20090176881 - Unsaturated alkyl esters of 5-aminolevulinic acid, their preparation and their use: Disclosed are unsaturated alkyl esters of 5-aminovulinic acid of the following chemical formula 1, or pharmaceutically acceptable salts thereof, a method for preparing the same, and uses thereof. [Chemical Formula I] NH2—CH2—CO—CH2—CH2—CO—O—R wherein, R is a group selected from a group consisting of 2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, cis-2-pentenyl, cis-3-hexenyl, cis-4-hexenyl,... Agent: Christie, Parker & Hale, LLP

20090176884 - Pharmaceutical suspension composition: An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and... Agent: Wyeth Patent Law Group

20090176883 - Trpa1 antagonists:

20090176885 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1;... Agent: Wellstat Management Company. LLC

20090176886 - Polymorphic forms of oseltamivir phosphate: The present invention relates to polymorphic forms of (3R,4R,5S)-5-amino-4-acetylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acid ethyl ester phosphate, which is a potent inhibitor of viral neuraminidase.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090176887 - Biocidal compositions and methods: Biocidal compositions comprises an effective amount of a biocidal agent such as a quaternary ammonium compound or a blend of quaternary ammonium compounds and an effective amount of a cellular membrane disruptor. The synergy index of the biocidal agent and the cellular membrane disruptor is less than 1. The biocidal... Agent: Mcandrews Held & Malloy, Ltd

20090176888 - Composition comprising phytosphingosine or derivative thereof: Provided is a composition for cancer treatment including phytosphingosine or a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.... Agent: Cantor Colburn, LLP

20090176889 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; q is 0 or 1; t is 0 or 1; R1 is alkyl... Agent: Wellstat Management Company. LLC

20090176890 - Edible plant extract based insecticidal composition: A food-grade insecticidal composition allowed for use in organic production which is effective in controlling insects, such as ants, aphids, mealy bugs, white flies, spider mites, leaf hoppers, cabbage loopers, leaf eating beetles and caterpillars, cockroaches, flies, wasps, mosquitoes, wood boring and eating insects, and body and head lice but... Agent: Connolly Bove Lodge & Hutz LLP

20090176891 - Dental composition and method of use: A dental composition for sealing a portion of a tooth includes a liquid acrylic or acrylate monomer, an acrylic or acrylate polymer that is soluble in the liquid acrylic or acrylate monomer, a photo-initiator for cross-linking the liquid acrylic or acrylate monomer, and a nanoparticle material dispersed within the composition.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090176892 - Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same: The present invention relates to a soluble hydrophobic-core carrier composition comprising (i) a linear polymeric backbone; (ii) a plurality of hydrophilic polymeric protective chains covalently linked and pendant to the polymeric backbone and (iii) at least one hydrophobic moiety covalently linked and pendant to the polymeric backbone. In certain embodiments,... Agent: Wilson Sonsini Goodrich And Rosati / Pharmain Ltd

  
07/02/2009 > patent applications in patent subcategories. category listing

20090170749 - Novel compounds which interact with pea-15: The present invention relates to novel pseudopeptide compounds of defined formula, capable of interacting with the PEA-15 protein and to the use thereof in screening methods and to a method of diagnosing pathological conditions which may involve PEA-15.... Agent: Oliff & Berridge, PLC

20090170748 - Plasmid mediated supplementation for treating chronically ill subjects: The present invention pertains to compositions and methods for plasmid-mediated supplementation. The compositions and methods are useful for treating anemia and other effects that are commonly associated in cancer bearing animals. Overall, the embodiments of the invention can be accomplished by delivering an effective amount of a nucleic acid expression... Agent: Jackson Walker LLP

20090170750 - Single-chain insulin: The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090170751 - Formation of superfibronectin by bbk32 and uses therefor: Provided herein is a method for inducing formation of a conformationally distinct superfibronectin by contacting plasma fibronectin with BBK32 protein or a BBK32 peptide and the BBK32-induced superfibronectin so formed. Also provided are methods of inhibiting endothelial cell proliferation, of treating pathophysiological conditions associated with endothelial cell proliferation and of... Agent: Benjamin Aaron Adler Adler & Associates

20090170752 - Reversal of adult onset disorders with granulocyte-colony stimulating factors: A method for treating adult onset neurodegenerative diseases and diabetes by administering an effective dose of Granulocyte-Colony Stimulating Factors.... Agent: Fitch Even Tabin And Flannery

20090170753 - Capsofungin formulations: The present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable salt of caspofungin as active ingredient being useful for the prevention and/or treatment of fungal infections. Said compositions additionally comprise specific bulking agents and small amounts or no amounts of an additional pH modifier and may be in a... Agent: Manelli Denison & Selter

20090170756 - Chimeric natriuretic peptides: Peptides of Dendroaspis, including chimeric peptides thereof, are provided, as well as methods of using the peptides as natriuretics, diuretics, and/or vasodilators.... Agent: Fish & Richardson P.C.

20090170758 - Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties: Pulmonary surfactants comprising additives, such as polymyxins, that improve their surface tension lowering properties. A method for improving the resistance to inactivation of a modified natural surfactant, such as one containing a lipid extract of minced mammalian lung comprising administering a surfactant in combination with a polymyxin.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090170755 - Cyclic peptide compounds: The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090170757 - Methods of using macrocyclic modulators of the ghrelin receptor: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin... Agent: Myers Bigel Sibley & Sajovec

20090170754 - Treating liver diseases: This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided.... Agent: Fish & Richardson P.C.

20090170776 - Angiogenically effective unit dose of fgf and method of administering: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition... Agent: Alston & Bird LLP

20090170771 - Anti-angiogenic agents and methods of their use: The present invention relates to the use of sFRP-4 and functional variants thereof as anti-angiogenic agents. It relates to methods of treatment and screening methods using sFRP-4 and functional variants thereof. Further, it relates to compositions, and in particular pharmaceutical composition, including sFRP-4 and functional variants thereof which may be... Agent: Edwards Angell Palmer & Dodge LLP

20090170760 - Anti-cancer agent comprising protein c inhibitor: The present invention provides anti-cancer agents comprising protein C inhibitor (PCI) or derivatives thereof as an active ingredient. The anti-cancer agents of the present invention have activities of suppressing cancer cell growth, and cancer metastasis, infiltration, and angiogenesis. Further, the present invention has shown that derivatives containing a heparin-binding domain... Agent: Fish & Richardson PC

20090170769 - Cell surface receptor isoforms and methods of identifying and using the same: Isoforms of cell surface receptors, including isoforms of receptor tyrosine kinases, and pharmaceutical compositions containing the isoforms are provided. Chimeras of and conjugates containing the cell surface receptors that contain a portion, such as an extracellular domain, from one cell surface receptor, and a second portion, particularly an intron-encoded portion,... Agent: Morrison & Foerster LLP

20090170766 - Chimeric kunitz domains and their use: The present invention relates to chimeras of human tissue factor inhibitor domain 1 with natural and non-natural Kunitz domains, and their preparation and use.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090170774 - Compositions and methods for enhancing fertility: Methods of promoting reproductive health in an animal by administering an effective amount of a composition containing at least one transfer factor are provided.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090170764 - Compositions containing anti-hiv peptides and methods for use: Peptides representing sequences from region 45-74 of the human CD38 leukocyte surface antigen are provided which may be used to inhibit or prevent transmission or replication of the HIV virus. The peptides have from 13 to 30 amino acids and include the amino acid sequence GPGTTK (SEQ ID for topical... Agent: Mccarter & English, LLP Hartford Cityplace I

20090170777 - Hsp therapy in conjunction with a low antigenicity diet: The present invention relates to a method for suppression, prevention, delaying the onset or treatment of diabetes, by administering to an individual in need thereof a fragment of Hsp60 or analog thereof in conjunction with a low antigenicity diet. The invention is exemplified using DiaPep277™, an analog of residues 437-460... Agent: Winston & Strawn LLP Patent Department

20090170772 - Interleukin production regulator, pharmaceutical composition or food comprising the interleukin production regulator, and method for production of the interleukin production regulator: Disclosed are: a method for producing an interleukin production regulator having both an effect of maintaining or promoting the production of interleukin-10 and an effect of maintaining or inhibiting the production of interleukin-12, comprising the step of disrupting a cell of a microorganism belonging to the genus Bifidobacterium; an interleukin... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090170770 - Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor: The invention relates generally to methods and compositions for treating conditions associated with angiogenesis, and, more specifically, the invention relates to methods and compositions for treating conditions associated with angiogenesis using vascular adhesion protein-1 (VAP-1) inhibitors. The invention also relates to methods and compositions for treating conditions associated with lymphangiogenesis... Agent: Goodwin Procter LLP Patent Administrator

20090170763 - Modified gherlin peptides: The present invention provides a novel peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090170759 - Neuroprotective peptides: Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological... Agent: Philip S. Johnson Johnson & Johnson

20090170773 - Novel use of g-protein-conjugated receptor and ligand thereof: The present invention provides a screening method for a substance that alters the bindability of RAIG2 or RAIG3 and glucose or 1,5-anhydroglucitol, including using RAIG2 or RAIG3 and glucose or 1,5-anhydroglucitol, and a regulator of sugar/lipid metabolism, a regulator of pancreas/pituitary function, a regulator of insulin secretion/blood glucose and ACTH... Agent: Leydig Voit & Mayer, Ltd

20090170765 - Peptide for inhibition of calcineurin: The present invention relates to a method for diagnosing susceptibility for a myocardial and/or immunological disorder, a kit and a therapeutic agent comprising a peptide of SEQ ID NO: 1 or 2 and uses thereof.... Agent: Jagtiani + Guttag

20090170778 - Pyy agonists and uses thereof: The invention provides PYY3-36 variants and pegylated derivatives thereof and compositions and methods useful in the treatment of conditions modulated by an NPY Y2 receptor agonist.... Agent: Pfizer Inc.

20090170767 - Soluble endoglin compounds for the treatment and prevention of cancer: Disclosed herein are soluble endoglin compounds and kits, pharmaceutical compositions, and articles of manufacture containing soluble endoglin compounds. Also disclosed herein are methods for treating an angiogenesis disorder, such as cancer, using soluble endoglin compounds, provided alone or in combination with a chemotherapeutic agent, an angiogenesis inhibitor, or an antiproliferative... Agent: Clark & Elbing LLP

20090170761 - Sustained release preparation of pro-insulin c-peptide: The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any... Agent: Knobbe Martens Olson & Bear LLP

20090170762 - Treatment of diabetes related obesity: Peptide analogues and uses are provided for treating and preventing obesity and for treating, preventing and reversing weight gain and related metabolic disease, and promoting weight loss and weight maintenance, by administering a medicament comprising an antagonist of GIP receptor, which is a peptide analogue of GIP.... Agent: K&l Gates LLP

20090170775 - Vasoactive intestinal polypeptide compositions: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed.... Agent: Howson & Howson LLP

20090170768 - Water-soluble carbon nanotube compositions for drug delivery and medicinal applications: Compositions comprising a plurality of functionalized carbon nanotubes and at least one type of payload molecule are provided herein. The compositions are soluble in water and PBS in some embodiments. In certain embodiments, the payload molecules are insoluble in water. Methods are described for making the compositions and administering the... Agent: Winstead PC

20090170779 - F11 receptor (f11r) antagonists as therapeutic agents: The present invention provides a cell adhesion molecule (CAM), designated F11 receptor (F11R), which is a member of the immunoglobulin super family localized on the surface of human platelets, and determined to effect platelet aggregation, secretion, platelet spreading and cellular adhesion. Cloned F11R cDNA and full length F11R cDNA and... Agent: Scully Scott Murphy & Presser, PC

20090170780 - Protection of the retina against laser injury by nap and related peptides: This invention relates to the use of ADNF polypeptides in the treatment of laser-induced retinal damage and related conditions.... Agent: Townsend And Townsend And Crew, LLP

20090170781 - Identification of immunologically effective epitopes on the surface of red blood cells and their use in a method of inducing tolerance thereto: The present invention relates to a method of identifying an immunologically effective epitope, the method comprising: a) preparing an oligomer of a protein present on the surface of a red blood cell which includes a polymorphism therein and b) ascertaining whether the oligomer stimulates T-cells and a composition comprising an... Agent: Licata & Tyrrell P.C.

20090170782 - Gnrh analogue formulations: The present invention relates to compositions forming a low viscosity mixture of: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one GnRH analogue; Wherein the pre-formulation forms, or is capable of forming, at least one... Agent: Nixon Peabody, LLP

20090170784 - Crystalline and amorphous forms of peptide: The present invention relates to the crystalline and amorphous structures of SEQ ID NO:1 (FLPS), methods of making the same and use in treatment of various diseases and conditions.... Agent: Wilson Sonsini Goodrich & Rosati

20090170783 - Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors: The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090170785 - Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application: The invention is related to the medicinal means of prevention and correction of age-related disorders of cellular and humoral immunity and may be used as a medication revealing an immunogeroprotective effect. There is proposed a peptide glutamyl-aspartyl-proline with general formula H-Glu-Asp-Pro-OH sequence 1 [SEQ ID NO:1], revealing an immunogeroprotective effect.... Agent: Leydig Voit & Mayer, Ltd

20090170786 - Methods for the use of branched chain amino acids: The invention provides an orally-administrable nutritional product comprising a dipeptide including a branched chain amino acid (BCAA). In one embodiment, the nutritional product comprises a dipeptide selected from at least one of the following: alanyl-leucine, alanyl-isoleucine, alanyl-valine, glycyl-leucine, glycyl-isoleucine, and glycyl-valine.... Agent: Nestle Healthcare Nutrition

20090170789 - Antioxidants for preventing and treating diseases caused by oxidative stress: Antioxidant compositions for the treatment and prophylaxis of illnesses associated with oxidative stress and lack of oxygen in the human body, comprising a complex of a metal selected from the group consisting of iron, copper, zinc and manganese with rutin and ascorbic acid and/or dihydroascorbic acid. Methods for synthesizing the... Agent: Stout, Uxa, Buyan & Mullins LLP

20090170787 - Cosmetic composition containing hydrolysates of icariin: The present invention relates to a cosmetic composition containing hydrolysates of icariin, and more particularly, a cosmetic composition containing hydrolysates of icariin including icaritin, icariside I and icariside II. The hydrolysates of icariin is prepared by a method comprising the steps of: (a) obtaining an extract from a plant containing... Agent: Nixon & Vanderhye, PC

20090170788 - Novel use of 1, 2, 3, 4, 6-penta-o-galloyl-beta-d-glucose: The present invention relates to novel use of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose. More particularly, the present invention relates to a pharmaceutical composition and cosmetic composition for preventing and treating skin disease, comprising 1,2,3,4,6-penta-O-galloyl-beta-D-glucose represented by formula 1 as an active ingredient. Also, the invention relates to a method for preventing and treating skin... Agent: Jhk Law

20090170790 - Ketolide derivatives as antibacterial agents: The present invention provides ketolide derivatives, which can be used as anti-bacterial agents. Compounds disclosed herein can be used for the treating or preventing conditions caused by or contributed to by gram positive, gram negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Moraxalla spp., Chlamydia... Agent: Ranbaxy Inc.

20090170791 - Macrolones: e

20090170793 - Artificial riboswitch for controlling pre-mrna splicing: The present invention relates to riboswitches that have been engineered to regulate pre-mRNA splicing. In particular, the insertion of a high affinity theophylline binding aptamer into the 3′ splice site region, 5′ splice site region, or branchpoint sequence (BPS) of a pre-mRNA modulates RNA splicing in the presence of theophylline.... Agent: Perkins Coie LLP

20090170800 - Genetic constructs and compositions comprising rre and cte and uses thereof: Genetic constructs that comprise a coding sequence for HIV-1 Rev, and a coding sequence for a desired protein are disclosed. Compositions that comprise at least two nucleic acid molecules in which at least one nucleic acid molecule comprises a coding sequence for HIV-1 Rev, and at least one nucleic acid... Agent: Pepper Hamilton LLP

20090170798 - Highly safe intranasally administrable gene vaccines for treating alzheimer's disease: An objective of the present invention is to provide a safe and effective vaccine therapy for Alzheimer's disease. A minus strand RNA viral vector carrying amyloid gene was constructed, and administered intranasally to 24- to 25-months-old APP transgenic mice. The level of serum anti-A 42 antibody was determined and showed... Agent: Clark & Elbing LLP

20090170796 - Histone demethylation mediated by the nuclear amine oxidase homolog lsd1: LSD1, a homolog of nuclear amine oxidases, functions as a histone demethylase and transcriptional co-repressor. LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription. Lysine demethylation occurs via an oxidation reaction that generates formaldehyde. Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4... Agent: Foley Hoag, LLP Patent Group (w/huv Hmv)

20090170797 - Hunk, a snfi-related kinase essential for mammary tumor metastasis: This invention relates generally to a novel serine/threonine protein kinase, specifically to hormonally up-regulated, neu-tumor-associated kinase (HUNK); and to the role of HUNK in tumor metastasis, primary tumor development, and the prediction of tumor behavior.... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090170795 - Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal: The present invention relates to a kit of parts comprising a nucleic acid sequence encoding a permease and a drug comprising one nucleobase moiety or a precursor thereof. The present invention further relates to a kit of parts comprising a precursor of a drug comprising a gene coding a permease... Agent: Buchanan, Ingersoll & Rooney PC

20090170802 - Method for producing polymers: e

20090170801 - Methods of treatment of cardiovascular and cerebrovascular diseases with fucoidan: A method for treating an ischemic cardiovascular or cerebrovascular disease comprising administrating to a patient in the need of such treatment a pharmaceutical composition comprising fucoidan.... Agent: Matthias Scholl

20090170799 - Modulation of c-reactive protein expression: Compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise oligonucleotides, targeted to nucleic acid encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for diagnosis and treatment of disease associated with expression of C-reactive protein are provided.... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20090170792 - Peptide ligands: A peptide consisting of or comprising an amino acid sequence selected from a ) Px1X2X3 T [SEQ.ID.NO.:11]; b) PSX4S [SEQ.ID.NO.:2]; C) QX5X6X7Q [SEQ.ID.NO.:3]; d) SX8S [SEQ-ID.NO.:4], in which X1, X2 and X3, which may be the same or different, each represents an amino acid residue; X4 represents an amino acid... Agent: Yankwich & Associates

20090170794 - Small interfering rnas that efficiently inhibit viral expression and methods of use thereof: The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) which are useful for inhibition of viralmediated gene expression. Small interfering RNAs as described herein may be used in methods of treatment of HCV infection. ShRNA and siRNA constructs that target the internal ribosome entry site... Agent: Wilmerhale/boston

20090170803 - Adjunctive treatment of biological diseases: The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2A adenosine receptor agonist. If no anti-pathogenic agent is known the A2A agonist can be used alone... Agent: Schwegman, Lundberg & Woessner, P.A.

20090170804 - Pirfenidone/toll-like receptor (tlr) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (g-csf): The invention disclosed herein relates to compositions and methods for treating subjects suffering from or at risk of developing neutropenia. In some embodiments, the methods comprise administering to a subject suffering from or at risk of developing neutropenia, an effective amount of pirfenidone and one or more toll-like receptor (TLR)... Agent: Marshall, Gerstein & Borun LLP

20090170805 - Anti-microbial agents and uses thereof: Many pathogens, including Mycobacterium tuberculosis and Yersinia pestis, rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a... Agent: Choate, Hall & Stewart LLP Sloan-kettering Institute For Cancer Research

20090170806 - Combination of alovudine and zidovudine in a molar ratio of 1:100 to 1:350: Co-administration of alovudine and zidovudine at ratios considerably in excess of the prior art completely or substantially abolishes the mitochondrial toxicity of alovudine in mitochondrial DNA depletion experiments. The invention thus provides pharmaceutical compositions comprising alovudine and zidovudine in a molar ratio in the range 1:100 to 1:350 and methods... Agent: Birch Stewart Kolasch & Birch

20090170807 - Methods and means for producing hyaluronan: The present invention relates to fungal cells and fungi which synthesize hyaluronan and to methods for preparing such fungi, and also to methods for preparing hyaluronan with the aid of these fungal cells or fungi. Furthermore, the present invention relates to the use of fungi for preparing hyaluronan and to... Agent: Hunton & Williams LLP Intellectual Property Department

20090170810 - Methods of treatment of cardiovascular and cerebrovascular diseases with low molecular weight fucoidan: A method for treating an ischemic cardiovascular or cerebrovascular disease comprising administrating to a patient in the need of such treatment a pharmaceutical composition comprising low molecular weight fucoidan.... Agent: Matthias Scholl

20090170808 - Oral agent for improving and protecting the function of joint comprising hyaluronic acid-phospholipid complexes: The present invention relates to an oral formulation comprising a hyaluronic acid-phospholipid complex, and to use of a hyaluronic acid-phospholipid complex for the manufacture of a joint function-improving and protecting agent for oral administration which can alleviate the arthritic symptoms in patients with arthritic conditions, increase the concentration of hyaluronic... Agent: Fish & Richardson P.C.

20090170809 - Pectic polysaccharides isolated from fruit pods of okra: The invention relates to a method for producing a high molecular weight pectin-like polysaccharide from fruit pods of okra. The high molecular weight pectin-like polysaccharide, when dissolved in a buffer, exhibit viscoelastic properties, and is very useful in applications such as ophthalmic surgery, dermatology and orthopedics.... Agent: Birch Stewart Kolasch & Birch

20090170811 - Composition for treatment of a detached retina and method of prodution thereof: The present invention relates to a composition for use in the treatment of a detached retina, comprising an oil and an additive capable of increasing the extensional viscosity of the oil. The present invention also relates to a method and kit of parts for producing the composition.... Agent: Lawson & Weitzen, LLP

20090170812 - Transcription factor modulating compounds and methods of use thereof: Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.... Agent: Mccarter & English, LLP Boston

20090170813 - Hypophosphorous acid derivatives and their therapeutical applications: Hypophosphorous acid derivatives having Formula (I) wherein .M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group, or an a, β, or a β, g-cyclic amino acid; .R1 is H or R, R being an hydroxy or a carboxy protecting group; .Z is H or an amino protecting group... Agent: Nixon & Vanderhye, PC

20090170814 - 7,8-bicycloakyl-chroman derivatives: p

20090170815 - Alendronate oral liquid formulations: The invention features an oral pharmaceutical solution comprising a therapeutically effective amount of alendronate or a salt thereof and a pharmaceutically acceptable liquid carrier. The solution is substantially free from degradation products, with the proviso that the solution has no buffer and no complexing agent. The oral solution avoids the... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090170816 - Combination comprising squalene, a phospholipid and an omega 3 fatty acid for the treatment of cancer: Pharmaceutical composition which comprises squalene or its pharmaceutically acceptable derivatives; at least one phospholipid, its salts or pharmaceutically acceptable derivatives; and at least one omega-3 fatty acid, its salts or pharmaceutically acceptable derivatives. Use of the composition in the preparation of a drug designed for the prophylaxis, treatment and/or improvement... Agent: Sughrue Mion, PLLC

20090170817 - Corrosion inhibition: The present invention relates to a method of preventing or alleviating the problems associated with corrosion and to novel formulations for use in such a method.... Agent: Hunton & Williams LLP Intellectual Property Department

20090170819 - (20r)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs: This invention discloses (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20R)-23,23-difluoro-1 α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090170818 - (20s)-23,23-difluoro-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs: This invention discloses (20S)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20S)-23,23-difluoro-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090170820 - 2-methylene-(20s,25r)-19,26-dinor-vitamin d analogs: This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20090170821 - 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs: This invention discloses 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,26-dinor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090170822 - 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin d analogs: This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1α-hydroxy-19,24,25,26,27-pentanor-vitamin D3, and pharmaceutical uses therefore. This compound exhibits activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as... Agent: Andrus, Sceales, Starke & Sawall, LLP

20090170823 - Dosage regimens and pharmaceutical compositions and packages for emergency contraception: The present invention is directed to dosage regimens for emergency contraception using nonsteroidal progestins and pharmaceutical compositions and packages thereof. Such regimens are useful for females in need of emergency contraception.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090170824 - Diarylsulfones as 5-ht2a antagonists: e

20090170825 - Beta-lactamylalkanoic acids for treating premenstrual disorders: 0-lactamyl alkanoic acids are described. Methods for treating various premenstrual disorders using or more O-lactamyl alkanoic acids are also described.... Agent: Barnes & Thornburg LLP

20090170827 - Acid addition salt of dihydropyridine derivative: There is provided an excellent medicine for treating or preventing hypertension or the like. A specific acid addition salt of 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester is useful as a medicine for treating or preventing hypertension or the like.... Agent: Birch Stewart Kolasch & Birch

20090170826 - Acid addition salt of optically active dihydropyridine derivative: There is provided an excellent medicine for treating or preventing hypertension or the like. A specific acid addition salt of (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenyl-methylazetidin-3-yl) ester 5-isopropyl ester is useful as a medicine for treating or preventing hypertension or the like.... Agent: Birch Stewart Kolasch & Birch

20090170828 - Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Azetidine derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes;... Agent: Merck And Co., Inc

20090170829 - Carboxamide, sulfonamide and amine compounds and methods for using the same: e

20090170830 - Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck And Co., Inc

20090170831 - Substituted lactams as inhibitors of abeta protein production: having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the... Agent: Kelley Drye & Warren LLP

20090170832 - Heterocyclic compounds having type i 11beta hydroxysteroid dehydrogenase inhibitory activity: v

20090170833 - Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them: A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090170834 - Fused pyrimidones and thiopyrimidones, and uses thereof: are useful, for example, in the effective killing or reduction in rate of proliferation of cancer cells, such as in patients suffering from cancer. In addition to the compounds themselves, the invention provides pharmaceutical compositions of the compounds and method of treatment using the compounds.... Agent: Ropes & Gray LLP

20090170835 - Isoindoline derivatives: e

20090170836 - New inhibitors of histone deacetylase:

20090170837 - Methods for treating ras driven cancer in a subject: The invention relates to the discovery that the dibenzodiazepinone analogues have growth inhibiting activities on tumorigenic cells that are driven by expression of RAS or mutated RAS. Thus the invention includes methods for inhibiting the activity of RAS using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven... Agent: Merchant & Gould PC

20090170838 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof: e

20090170839 - Aerosol formulation for inhalation containing an anticholinergic agent: The invention relates to specific aqueous aerosol formulations that are devoid of propellant, containing one or more anticholinergic agents of formula (1), in which X represents an anion, and containing at least one pharmacologically compatible organic acid and optionally additional pharmacologically compatible adjuvants and/or complexing agents. The cation of formula... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090170840 - Ns1 protein inhibitors: The present invention generally relates to compounds to treat viral infections and methods of their use. In particular, compounds of the present invention inhibit the activity of NS1 protein, thereby mitigating viral infection and, in particular, influenza virus infection. Accordingly, NS1 protein inhibitors and methods of treatment that employ such... Agent: Fulbright & Jaworski L.L.P.

20090170842 - Brca1-based breast or ovarian cancer prevention agents and methods of use: A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral,... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090170841 - Styrenyl derivative compounds for treating ophthalmic diseases and disorders: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders,... Agent: Wilson Sonsini Goodrich & Rosati

20090170843 - (poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents: The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.... Agent: Birch Stewart Kolasch & Birch

20090170844 - Spiro tetracyclic compound: Disclosed is an anti-coagulant which has extremely excellent inhibitory effect on FXa and an extremely poor inhibitory effect on hERG channel, and can be administered through the oral route. Specifically, disclosed is a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof.... Agent: Birch Stewart Kolasch & Birch

20090170845 - Use of imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain: s

20090170847 - Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same: The inventive imidazopyridine derivative can be used in a pharmaceutical composition for preventing or treating diseases such as diabetes, obesity, dementia, cancer, and inflammation, since it can efficiently inhibit the activities of several protein kinases including glycogen synthase kinase-3 (GSK-3), aurora kinase, extracellular signal-regulated kinase (ERK), protein kinase B (AKT),... Agent: Baker Botts L.L.P.

20090170846 - Inhibitors of the hiv integrase enzyme: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus “HIV” integrase enzyme. Formula (I).... Agent: Pfizer Inc Mary J Hosley

20090170848 - Thiazolones for use as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090170849 - Quinazolinone derivatives having b-raf inhibitory activity: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the... Agent: Astrazeneca R&d Boston

20090170850 - Cycloalkyl derivatives of 3-hydroxy-4-pyridinones: wherein R1 is X with the proviso that R2 is Y; or R1 is T with the proviso that R2 is W; or R1 is X with the proviso that R2R5N when taken together form a heterocyclic ring selected from piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl, wherein the group piperidinyl, morpholinyl,... Agent: Apotex, Inc.

20090170851 - Chroman compounds: e

20090170852 - Novel pyrazole-based hmg coa reductase inhibitors: Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic... Agent: Pfizer Inc.

20090170853 - Novel inhibitors of kinases: v

20090170856 - Heterocyclic antiviral compounds: Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090170855 - Hiv inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones: m

20090170857 - Method for healing a wound using a direct vasodilator: A method for healing a wound comprising the step of topically administering a wound healing composition to a wounded area, wherein the wound healing composition comprises a first medicament characterized as a direct vasodilator and pharmaceutically acceptable salts thereof.... Agent: King & Partners, PLC

20090170854 - New use: The present invention relates to a new use of certain pharmaceutically active compounds in the treatment and/or prevention of medicament induced gastric ulcer. More particularly the invention is directed to the use of said compounds, and pharmaceutically acceptable salts thereof, for the treatment and/or prevention of NSAID (non-steroidal antiinflammatory drugs)... Agent: White & Case LLP Patent Department

20090170858 - Methods and compositions containing natural folates for protecting against radiation damage: Disclosed are methods for protecting a subject from harmful effects of ionizing radiation. The method includes administering to the subject an effective amount of at least one reduced folate. Also disclosed are radioprotective compositions that include a first radioprotective agent and a second radioprotective agent, where the first radioprotective agent... Agent: Peter Rogalskyj, Esq. The Law Office Of Peter Rogalskyj

20090170859 - Viral polymerase inhibitors: s

20090170860 - Use of parp-1 inhibitors: A method for improving the cytotoxic effect of Ecteinascidin-743 (ET-743) or an analog thereof on a tumor cell population in a patient the method including administering to the patient, sequentially or simultaneously, a therapeutically effective combination of a composition including ET-743 and an amount of a composition including a PARP-1... Agent: King & Spalding

20090170861 - Pyridazinone derivatives useful as glucan synthase inhibitors: In its many embodiments, the present invention provides -substituted pyridazinone compounds as glucan synthase inhibitors, methods of preparing such compounds, pharmaceutical including one or more of such compounds, methods of preparing pharmaceutical formulations including one or more such compounds or one or more such compounds along with other antifungal agents,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090170862 - Use of c-kit inhibitors for the treatment of myeloma: wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of myeloma, in particular multiple myeloma, especially myeloma which is resistant to conventional chemotherapy; to a combination comprising a c-kit inhibitor and a compound effecting apoptosis of myeloma... Agent: Novartis Corporate Intellectual Property

20090170863 - Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators: Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction,... Agent: Merck And Co., Inc

20090170864 - Diacylglycerol acyltransferase inhibitors: r

20090170865 - Treatment of prostate cancer with angiogenesis-targeting quinazoline-based anti-cancer compounds: Provided is a method of inhibiting the growth of prostate cancer cells comprising administering an effective amount of DZ-50 (2-[4-biphenyl-4-sulfonyl)-piperazin-1-yl]-6,7-diisopropoxyquinazolin-4-yl-amine) to a patient in need thereof. In another aspect, a method is provided for inhibiting the initiation of prostate cancer comprising administering an effective amount of DZ-50 to a patient... Agent: Crowell & Moring LLP Intellectual Property Group

20090170866 - Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers: The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.... Agent: Bristol - Myers Squibb Company Patent Department

20090170867 - Trpv1 antagonists including sulfonamide substituent and uses thereof: and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA′ or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090170868 - Trpv1 antagonists including dihydroxy substituent and uses thereof: and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount... Agent: Dechert LLP

20090170869 - Piperazine derivative having affinity for the histamine h3 receptor: d

20090170870 - Amidine-containing compounds useful as muscarinic receptor antagonists: or a pharmaceutically acceptable salt thereof, where R1-3, R5, R7, a, b, Q, X, X′, X″, Y, Z, and Ar are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also relates to pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of... Agent: Theravance, Inc.

20090170871 - Il-8 receptor antagonists: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090170872 - Compounds and their pharmaceutical use: The present invention relates to novel compounds of the general formula (I), their analogs, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions. The present invention more particularly provides novel compounds of the general formula (I).... Agent: Birch Stewart Kolasch & Birch

20090170875 - Compounds for the treatment of inflammatory disorders: e

20090170873 - Pyrazole-substituted arylamides as p2x3 and p2x2/3 antagonists:

20090170874 - Triazole-substituted arylamides as p2x3 and p2x2/3 antagonists:

20090170876 - Novel topical formulations of flucytosine: The invention relates to topical formulations of flucytosine which demonstrate a clear advantage over currently available therapeutic regimens for the treatment and maintenance of fungal infections, particularly vulvovaginal candidiasis. The invention provides compositions which solve the long-standing need for antimicrobial agents which treat effectively resistant strains of Candida spp., especially... Agent: Dinsmore & Shohl, LLP

20090170877 - 5,6-trimethylenepyrimidin-4-one compounds: e

20090170878 - Macrocyclic compounds useful as bace inhibitors:

20090170879 - 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions: Certain 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are provided. These 6,9-disubstituted purine derivatives and their pharmaceutically acceptable salts are useful in compositions for treating mammalian cells, and especially human skin cells, in order to ameliorate the adverse effects of aging, treat skin disease states, treat immunological responses resulting... Agent: Fitch Even Tabin And Flannery

20090170881 - New inhibitors of histone deacetylase: r

20090170880 - Methods and means for the treatment of cancer: Provided are Breast Cancer Resistance Protein (BCRP) inhibitors, P-glycoprotein (P-gp) inhibitors and chemotherapeutic agents for use in the treatment of cancer by combination therapy of the BCRP inhibitor and/or P-gp inhibitor with the chemotherapeutic agent. The chemotherapeutic agent is an imidazotetrazine, e.g. temozolomide.... Agent: Swanson & Bratschun, L.L.C.

20090170882 - Methods and compositions: Compounds, compositions and methods relating to kinesin inhibition are described herein.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090170883 - 3-arylphenyl sulfide derivative and insecticide and miticide: (wherein R is a C2-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group or the like, B0 to B2 and B3 are hydrogen atoms, halogen atoms, cyano groups, C1-C4 haloalkyl groups or the like, n is 0, 1 or 2, and Ar is a phenyl ring, a pyridine... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090170884 - Fungicidal active substance combination: h

20090170885 - Naphthyridine derivatives as potassium channel modulators: The invention also provides a composition comprising a pharmaceutically acceptable carrier or excipient and at least one of the following: a pharmaceutically effective amount of a compound of formula I; a pharmaceutically acceptable salt of a compound of formula I; a pharmaceutically acceptable ester of a compound of formula I.... Agent: Mcdermott, Will & Emery

20090170886 - Androgen modulators: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.... Agent: Pfizer Inc.

20090170887 - Novel indazole derivative having spiro ring structure in side chain: An object of the present invention is to create a novel indazole derivative having a spiro ring structure in a side chain, which is useful as a pharmaceutical, and to find a new pharmacological activity of the derivative. The present invention compound is represented by the general formula [I] and... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090170888 - Antipruritic agent for pruritus caused by multiple sclerosis: An antipruritic against pruritus caused by multiple sclerosis is disclosed. The antipruritic comprises as an effective ingredient an κ opioid receptor agonist compound having a 4,5-epoxymorphinan skeleton and having a specific chemical structure, such as Compound 1 having the following structure:... Agent: Birch Stewart Kolasch & Birch

20090170889 - Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders: The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090170890 - Methohds of inhibiting viral infection: A method of inhibiting viral infection in a mammal in need of same, includes administering an effective amount of at least one of the compounds of FGI-103 which are represented by 273, 365 and 510 either prophylactically to prevent viral infection, or therapeutically following viral infection. These compounds appear to... Agent: Steven B. Kelber

20090170891 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: m

20090170892 - 3-hydroxy-6-phenylphenanthridines as pde4 inhibitors:

20090170893 - Novel hydrate form: The present invention relates to a novel hydrate form of moxifloxacin monohydrochloride, processes for preparing the form, pharmaceutical compositions comprising the form and uses of the form and compositions.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090170894 - Urea derivatives of tropane, their preparation and their therapeutic application: e

20090170895 - S1p3 receptor antagonist: wherein R1 represents a C2-C8 alkyl group which may be substituted, a phenyl group which may be substituted, an aromatic heterocyclic group which may be substituted, a C2-C8 alkoxy group which may be substituted, or —NR4R5 (wherein R4 and R5, which are identical or different, each represent a hydrogen atom... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090170896 - C-met modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways... Agent: Leydig Voit & Mayer, Ltd

20090170897 - Method of treating neuropathic pain: The invention relates to the use of a CRTH2 receptor antagonist in the manufacture of a medicament for the treatment of neuropathic pain and to a method of treating neuropathic pain using an antagonist of CRTH2 receptor.... Agent: Pfizer Inc.

20090170898 - Sulphonamide derivatives as modulators of the glucocorticoid receptor: e

20090170899 - Stimulators of 5-ht4 receptors and uses thereof: The present invention relates to a novel combination of a serotonin selective re-uptake inhibitor (SSRI) and an agonist of the serotonin 4 (5-HT4) receptor to augment and/or provide faster onset of the therapeutic effect of the SSRI alone or administered with any other compound which causes an elevation in the... Agent: Smart & Biggar P.o. Box 2999, Station D

20090170900 - Dosing regimen for weight loss: Disclosed are dosing regimens and methods for the treatment of obesity, overweight and/or overeating in mammals comprising administering to the mammal a pharmaceutically effective amount of a CB1 receptor antagonist as a unit dosage according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly... Agent: Bennett Jones LLP C/o Ms Roseann Caldwell

20090170901 - Benzoyl urea derivatives: The new benzoyl urea derivatives of formula (I) wherein the meaning of X and Y independently are hydrogen atom, hydroxy, benzyloxy, amino, nitro, C1-C4 alkylsulfonamido optionally substituted with a halogen atom or halogen atoms, C1-C4 alkanoylamido optionally substituted with a halogen atom or halogen atoms, C1-C4 alkoxy, aroyl-carbamoyl optionally substituted... Agent: K.f. Ross P.C.

20090170902 - Compounds which potentiate glutamate receptor and uses thereof in medicine: wherein Ar is selected from phenyl, pyridyl, furanyl and thienyl, each optionally substituted with one or more groups Y; and each Y group is independently selected from the group consisting of: halo, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, cyano, C(O)C1-4alkyl, NHSO2C1-4alkyl, NMeSO2C1-4alkyl, NHCOC1-4alkyl, NMeCOC1-4alkyl, SOC1-4alkyl, SO2C1-4alkyl, and CO2C1-4alkyl, or two Y groups together... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090170903 - Ester derivatives as phosphodiesterase inhibitors: The invention provides inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are new ester derivatives, methods of preparing such compounds, compositions containing them, and therapeutic uses thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090170905 - Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid: The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.... Agent: Vertex Pharmaceuticals Inc.

20090170904 - Substituted benzimidazoles and methods of their use: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and... Agent: Novartis Vaccines And Diagnostics Inc.

20090170906 - Hcv inhibitors: The present invention relates to compounds that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compounds useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090170907 - Chemical compounds: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090170908 - Spiro compounds and pharmaceutical use thereof: The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof... Agent: Fish & Richardson PC

20090170909 - Alpha ketoamide compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Townsend And Townsend And Crew, LLP

20090170910 - Wound healing: The present invention relates to the use of p38 MAP kinase inhibitors and p38 MAP kinase inhibition to promote wound healing.... Agent: Morgan, Lewis & Bockius LLP

20090170911 - Novel azole compound: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090170912 - Agents for combating plant pests: e

20090170914 - Cermide kinase modulation: A compound of formula (I) wherein R1 is a straight chain, branched or cyclic aliphatic, aromatic or heterocyclyl group comprising at least 8 carbon atoms, e.g. 8 to 22, R2 is a straight chain, branched or cyclic aliphatic, aromatic or heterocyclic group comprising from 1 to 12 carbon atoms, and... Agent: Charles E. Lykes, Jr.

20090170913 - Novel mch receptor antagonists: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and... Agent: Eli Lilly & Company

20090170915 - Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)uriedo)phenyl)ethylcarbamate: The present invention relates to polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethylcarbamate, pharmaceutical compositions thereof, processes to prepare therein, and uses therewith.... Agent: Vertex Pharmaceuticals Inc.

20090170916 - Pyrrole and pyrazole daao inhibitors: e

20090170917 - Acid mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing... Agent: Choate, Hall & Stewart LLP

20090170918 - Solid formulation of fungicidal mixtures: o

20090170919 - Methods for treatment of inflammatory diseases: An improved method of treating skin diseases comprises applying to the skin of a patient suffering such a skin disease an allantoin-containing composition in a therapeutically effective quantity. The allantoin-containing composition is an oil-in-water emulsion that includes allantoin and an emulsifier system that includes at least one emulsifier that is... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20090170920 - Substituted hydantoins:

20090170921 - Benzimidazole derivatives:

20090170922 - Benzimidazole derivatives and their use as a medicament:

20090170923 - Hcv inhibitors: The present invention relates to compounds that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compounds useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090170924 - N-phenethylcarboxamide derivatives: e

20090170925 - Methods for prognosing the ability of a zearalenone analog compound to treat cancer: The instant invention provides methods of prognosing the ability of a zearalenone analog compound to treat a cancer in a subject, methods of prognosing the ability of a zearalenone analog compound to inhibit the growth of a cancer in a subject, and methods of prognosing the ability of a zearalenone... Agent: Lahive & Cockfield, LLP/eisai Floor 30, Suite 3000

20090170926 - Antiviral agents: The present invention provides a method of treatment or prophylaxis of hepatitis B virus in a subject comprising administering an effective amount of a compound of formula (1) or a pharmaceutically acceptable derivative, salt or prodrug thereof. In addition, there is provided compounds of formula (1) and pharmaceutical compositions thereof.... Agent: Seed Intellectual Property Law Group PLLC

20090170927 - Functionalized phenolic compounds and polymers therefrom: e

20090170929 - Composition for the protection and preservation of organs, tissues or cells and the use thereof: The present invention provides a composition for efficiently protecting and preserving organs, tissues or cells. In particular, the present invention provides a protective composition which can be used during operations. Specifically, the present invention provides a composition for protecting and preserving organs, tissues or cells, comprising a polyphenol. A method... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090170928 - Synthesis of oligo/poly(catechins) and methods of use: A method for synthesizing a biocompatible, water-soluble oligo/polyflavanoid, includes polymerizing an optionally substituted flavanoid with a polymerization agent in the presence of a biocompatible polymerization solubilizer, thereby producing the biocompatible, soluble oligo/polyflavanoid. Also included is a biocompatible, soluble, oligo/polyflavanoid or a pharmaceutically acceptable salt, solvate, or complex thereof. Also included... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090170930 - Methods for directing differentiation of clonogenic neural stem cells with coumarins: A method for promoting differentiation of clonogenic neural stem cells (NSCs), comprising administering to a patient in the need of such promoting a coumarin compound represented by formula I or by formula II. The representative coumarin compounds include 7-hydroxycoumarin, daphnoretin, scopoletin, edgeworin, aesculetin and esculetin-6-β-D-glucopyranoside. The coumarin compounds showed significant... Agent: Matthias Scholl

20090170931 - Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.... Agent: Jacqueline S Larson

20090170932 - Disinfectant compositions, methods and systems: Disinfectant compositions comprising N-Acetyl Cysteine (NAC) and Vitamin C are disclosed. The disinfectant compositions have also demonstrated activity in inhibiting as well as killing micro-organisms responsible for generating biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to reduce the proliferation of and/or... Agent: Buchanan Ingersoll & Rooney, PC

20090170933 - Method for removing a medical device from a spasmodic constriction in a bodily passageway: A method and apparatus for removing a medical device entrapped in a bodily passageway resulting from a spasmodic constriction of bodily tissue surrounding the device involves delivering to the site of the constriction an amount of an antispasmodic agent sufficient to relax the surrounding bodily tissue. The method may also... Agent: Brinks Hofer Gilson & Lione/indy/cook

20090170934 - Manufacturing process for no-donating compounds such as no-donating diclofenac: The present invention relates to a new process for the preparation of NO-donating compounds using a sulfonated intermediate. The invention relates to new intermediates prepared therein suitable for large scale manufacturing of NO-donating compounds. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically... Agent: Arent Fox LLP

20090170936 - Ester compound and its use: e

20090170935 - Novel formulations of bifenthrin and enriched cypermethrin: The present invention is directed to novel insecticidal compositions comprising bifenthrin and enriched cypermethrin, the compositions are physically stable when diluted with water.... Agent: Patent Administrator Fmc Corporation

20090170937 - Amino acid derivatives: wherein: R1 is a carboxyl, carboxyl ester, or carboxamide group; R2 and R3 are independently hydrogen, or a group —C(═O)R6 or —C(═O)OR6 wherein Re is C1-C6 alkyl, or a group —CH2Q wherein Q is an optionally substituted monocyclic carbocyclic or heterocyclyl ring of 3 to 6 ring atoms; R4 and... Agent: Banner & Witcoff, Ltd.

20090170938 - Fungicidal active ingredient combination: e

20090170939 - Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy: This invention relates to the use of fenofibrate or a derivative thereof for the manufacture of a medicament for the prevention and/or treatment of retinopathy.... Agent: Crowell & Moring LLP Intellectual Property Group

20090170940 - Modified ethyl formate compositions and methods for soil fumigation: Slow-flow, modified ethyl formate compositions and methods for their use as pre-plant soil fumigants (controlling nematodes and other pathogens) are provided. The modifications include adding to ethyl formate a viscosity modifying thickening agent, and one or more substances which function as a co-solvent and dilution agent (the co-solvent and dilution... Agent: Marc J. Farrell, Esq.

20090170941 - Pharmaceutical compounds: Compounds or their salts of general formula (I): A-B—N(O)s wherein: s is an integer equal to 1 or 2; A=R-T1-, wherein R is the drug radical and T1=(CO)t or (X)t′, wherein X=O, S, NR1c, R1c is H or a linear or branched alkyl or a free valence, t and t′... Agent: Arent Fox LLP

20090170942 - Ester derivative and use thereof: Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=0 to 8, R1 and R2 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that when X1 is a methylene group, then... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090170943 - Spider esters in personal care applications: The present invention is drawn to a process for providing emolliency to the skin using a series so called “spider esters”. These esters are derived from poly-hydroxy functional compounds sequentially reacted with ethylene oxide or propylene oxide, followed by the reaction of the alkoxylate with fatty acid. The resulting products... Agent: Anthony J O'lenick Jr

20090170944 - Ophthalmic micellar compositions with enhanced stability: This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C16, wherein the pharmaceutically active substance exhibits an... Agent: Young & Thompson

20090170946 - Composition for mold remediation: An anti-fungal composition is disclosed and has enhanced microbiocidal activities for killing or inhibiting growth of live mold cells and spores. Further, the composition stops the production of mycotoxins associated with molds. Included among the molds vulnerable to the composition are black mold, Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Stachybotrys... Agent: Nydegger & Associates

20090170945 - Pregabalin salts: Pregabalin besylate and pregabalin tosylate are pharmaceutically acceptable acid addition salts of pregabalin that are isolatable in solid state, particularly crystalline state, sufficiently soluble in water, and stable both in the solid state and in the solution.... Agent: SynthonIPInc

20090170947 - Disinfectant compositions, methods and systems: Disinfectant compositions comprising PHMB and EDTA salt(s) are disclosed. The disinfectant compositions have also demonstrated activity as enhanced, fast acting catheter lock/flush solutions. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing... Agent: Buchanan Ingersoll & Rooney, PC

20090170948 - Crystal forms of o-desmethylvenlafaxine fumarate: Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical compositions thereof.... Agent: Kenyon & Kenyon LLP

20090170949 - Method to control body weight: The present invention relates to a method to treat obesity and/or a method to lose or control body weight. More specifically, the invention relates to the use of a compound inhibiting the sweet taste perception, preferably by inactivating the T1R3 receptor, for the preparation of a medicament to treat or... Agent: Nixon & Vanderhye, PC

20090170950 - Inhibitors of neurotrypsin: e

20090170951 - Phenolic hydrazone macrophage migration inhibitory factor inhibitors: Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal... Agent: Amster, Rothstein & Ebenstein LLP

20090170952 - Colchicine compositions and methods: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.... Agent: Cantor Colburn, LLP

20090170953 - Indentification of compounds that inhibit replication of human immunodeficiency virus: The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum.... Agent: Knobbe Martens Olson & Bear LLP

20090170954 - Process for recovering florfenicol and florfenicol analogs: This invention is generally directed to a method for recovering florfenicol and florfenicol analogs from pharmaceutical compositions. The recovered florfenicol and analogs can be, for example, reused to make new pharmaceutical compositions and thereby reduce the need and expense of manufacturing new florfenicol and florfenicol analogs.... Agent: Intervet/schering-plough Animal Health Patent Department

20090170955 - Fast release paracetamol tablets: A pharmaceutical composition such as a swallow tablet or capsule formulation is described comprising paracetamol, calcium carbonate, at least one binding agent and at least one disintegrating agent in the form of a granulate, optionally combined with one or more pharmaceutically acceptable extragranular components.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090170956 - Preparation and the use of ethoxy combretastatins and their prodrugs: The invention disclosed a total synthesis process of novel ethoxy combretastatins and their prodrugs. Combretastatins are chemically modified by ethoxy substituted on the 4′-position of their B aryl ring and are converted to be their soluble prodrugs of phosphate or their inner salt of phosphorylcholine by modifying the hydroxyl on... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090170957 - Scyllo-inositol derivatives and their use in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence: Scyllo-Inositol derivatives represented by structural formula II are described, wherein at least one and not more than five of R1, R2, R3, R4, R5 and R6 is hydroxyl and the other of R1, R2, R3, R4, R5 and R6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090170958 - Use of particular polymers or copolymers as surfactants for stabilizing latices: The invention relates to a composition comprising a latex and at least one copolymer that may be obtained via a monomer polymerization process, comprising a step of placing in contact, in a medium comprising water, the said monomer(s) with at least one initiator corresponding, for example, to the formula:... Agent: Millen, White, Zelano & Branigan, P.C.

20090170960 - Peptide lipid-containing carrier and method for introducing compound into cells using same: The present invention provides a carrier capable of highly efficiently introducing a compound into cells with low cytotoxicity, which contains peptide lipids represented by the following formula, and a method for introducing a compound into cells using the carrier: wherein R1 is an amino acid or peptide having 1-10 amino... Agent: Leydig Voit & Mayer, Ltd

20090170959 - Polymer carrier: Compositions and methods for delivering bioactive agents, such as vitamins, hormones, nutrients and drugs, by stabilizing and or solubilizing these agents in a polymer matrix. The carrier polymers can be used in drug delivery and are useful for delivery of small molecules. The carrier polymers also can be used in... Agent: Smith, Gambrell & Russell

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140410: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.67113 seconds

PATENT INFO